Trading Analysis Report: NBIS¶

Generated: 2026-10-02 10:04:00

I. Analyst Team Reports¶

Market Analyst¶

Current Price: 232.28 USD Price As Of: 2026-10-01

NBIS (Nebius Group N.V.) – Technical Analysis Report¶

Data note: The session context said today was 2026-10-02, but the task said to treat 2026-10-01 as "now". The verified snapshot's latest bar is 2026-10-01, so all figures use that date. The snapshot and the indicator tools agreed on every value I compared (RSI, MACD, ATR). I found no discrepancies.

1. Indicators chosen and why¶

Role	Indicator	Why it fits NBIS now
Trend (long-term)	close_50_sma / close_200_sma (from the verified snapshot)	The stock has been through large swings, so the long-term averages show where the structural trend sits.
Trend (multi-timeframe)	supertrend	It gives a weekly, monthly and daily trailing stop. These are useful reference points for risk on such a volatile name.
Trend strength	adx	Tests whether the current trend is tradable or just choppy.
Momentum	macd (with signal and histogram from the snapshot)	Shows the short-term momentum shift after the September swings.
Momentum / overbought-oversold	rsi	A simple read on whether price is stretched.
Volatility	atr (plus Bollinger bands from the snapshot)	Daily ranges are large, so ATR is needed for stop and position sizing.
Volume	obv	Checks whether volume supports the September swings.
Exhaustion	td_9	Flags any trend exhaustion on three timeframes.
Stretch	z_score	Measures distance from the 20-period mean on three timeframes.

I used mfi, stochrsi and kdj in none of these roles. They would mostly repeat what rsi and obv already show.

2. Price structure and context¶

Rally since April: NBIS closed at 101.95 on 2026-04-01. It peaked at a closing high of 286.69 on 2026-06-18, with an intraday high of 299.86 on 2026-06-22.
July sell-off: It then fell to a closing low of 148.22 on 2026-07-29 (volume 39.8M, intraday low 145.80). That low is still well above the April start.
August spike: On 2026-08-12 the stock jumped from 193.23 to 259.20 on 63.5M shares, the heaviest volume in the sample. It reached 277.68 on 2026-08-14 and gave back most of the move by 2026-08-19 (223.90, 50.4M volume).
September range:
It bottomed at 199.54 on 09-01.
It rallied to 243.88 on 09-08.
It dropped to 207.37 on 09-15.
It rallied again to 243.48 on 09-24.
It now sits at 232.28.
This is a choppy range of roughly 200 to 245 on closing prices, not a clean trend.
Last four sessions: Closes went 237.33, 231.88, 237.35, 235.88, then 232.28. Volume was 11–15M, well below the spike days, so there is no strong conviction either way.

3. Trend¶

Moving averages are bullish in order:
Price (232.28) is above the 50 SMA (218.41) and well above the 200 SMA (166.93).
The 10 EMA (232.22) is almost exactly at price, so short-term momentum is neutral.
The 50 SMA is above the 200 SMA, which is a constructive long-term structure.
SuperTrend is UP on all three timeframes:
Weekly (primary): stop 172.93, with the close 34.32% above it.
Monthly: stop 113.82, with the close 104.08% above it.
Daily: stop 195.10, with the close 19.06% above it.
Nothing has flipped. The weekly and monthly trends are intact.
ADX is only 18.64, below the 20 range-bound threshold and down from 20.25 on 09-30. It was about 5–6 in early September, so trend strength has risen but is still not confirmed. The data fits a trending long-term picture with a range-bound short term. Trend-following signals are less reliable until ADX holds above about 25.

4. Momentum¶

MACD is 4.52 against a signal of 3.71, so the histogram is +0.81. That is mildly bullish.
MACD was negative in early September (−2.06 on 09-03).
It turned positive on 09-08 and peaked at 4.78 on 09-30.
The latest reading is down slightly, so upside momentum is fading a little. There is no bearish cross yet.
RSI is 52.77, which is neutral. It peaked at 58.49 on 09-08 and 58.30 on 09-24. It has not come near 70, so the stock is not overbought.

5. Volatility and risk¶

ATR is 16.07, about 6.9% of the price. It has eased from 19.52 on 09-01, so volatility is cooling but still high. Typical daily ranges of 15–20 points should shape stop distances and position size.
Bollinger bands: the middle is 227.91, the upper 250.68 and the lower 205.13. Price sits slightly above the middle, with the band edges about 18 points above and 27 points below.
Sizing example (illustrative): a stop 2× ATR below the close would be about 200, near the 09-01 close of 199.54. It would also sit just above the daily SuperTrend stop of 195.10.

6. Volume¶

OBV is 484.3M, down from a September high of 522.0M on 09-24 but well above 406.5M on 09-01.
At nearly the same price on 09-08 (243.88) and 09-24 (243.48), OBV was higher the second time (469.7M versus 522.0M). That suggests modest accumulation across the September swings.
The latest pullback has mostly come on lower volume, which is not a distribution signal. OBV is still below its 09-24 high, though, so there is no new volume confirmation.

7. Exhaustion and stretch¶

TD-9: weekly −3 (sell setup, 3 of 9), monthly +1, daily +2. All counts are early. There is no exhaustion signal on any timeframe.
Z-score: weekly +0.34, monthly +1.39, daily +0.38. The weekly and daily readings are near fair value. The monthly reading is moderately elevated but below the ±2 threshold. Price is not statistically stretched.

8. Key levels (from the data above)¶

Resistance:
243.48–243.88, the closing highs of 09-24 and 09-08.
250.68, the upper Bollinger band.
254.74, the intraday high on 09-08.
277.68, the August closing high.
286.69, the June closing high.
Support:
232.22, the 10 EMA.
227.91, the Bollinger middle.
218.41, the 50 SMA.
205.13, the lower Bollinger band, and 207.37, the 09-15 close.
199.54, the 09-01 close.
195.10, the daily SuperTrend stop.
172.93, the weekly SuperTrend stop.
These are reference levels from the data. I have not verified any past bounces off them.

9. Scenarios (for the decision-making agent)¶

Constructive case: a close above about 243.88 with rising volume and ADX moving above 25 would confirm a breakout from the September range. The next upside reference would be 250.68, then 277.68.
Neutral case (most likely given ADX 18.6, RSI 52.8 and z-score near 0): continued chop between about 205 and 245. Mean-reversion trades between the Bollinger band edges would fit better than trend-following.
Bearish case: a close below the 50 SMA (218.41) and then below 205 to 207 would end the higher-low sequence from September. A bearish MACD cross (histogram below 0) would add confirmation. The daily SuperTrend at 195.10 would be the next major test before the weekly stop at 172.93.

10. Summary¶

The long-term trend is up, with all three SuperTrend timeframes and the moving-average ordering positive. The short-term setup is neutral. Price sits at its 10 EMA, ADX is below 20, RSI is mid-range, and neither TD-9 nor z-score shows stretch. Volatility is high at about 7% of price per day, so position sizing matters more than the direction call.

Category	Indicator	Latest value	Reading
Price	Close (2026-10-01)	232.28	Open 236.18, high 239.63, low 228.47, volume 12.27M
Trend	10 EMA	232.22	Price is right at it, so short-term momentum is neutral
Trend	50 SMA	218.41	Price above it; medium-term support reference
Trend	200 SMA	166.93	Price well above it; long-term trend is up
Trend	SuperTrend weekly	UP, stop 172.93	Close 34.32% above the stop
Trend	SuperTrend monthly	UP, stop 113.82	Close 104.08% above the stop
Trend	SuperTrend daily	UP, stop 195.10	Close 19.06% above the stop
Trend strength	ADX	18.64	Below 20, so range-bound; down from 20.25 on 09-30
Momentum	MACD / signal / histogram	4.52 / 3.71 / +0.81	Mildly bullish; MACD slipping from 4.78 on 09-30
Momentum	RSI	52.77	Neutral
Volatility	ATR	16.07	About 6.9% of price; down from 19.52 on 09-01
Volatility	Bollinger lower / middle / upper	205.13 / 227.91 / 250.68	Price slightly above the middle
Volume	OBV	484.3M	Below the 09-24 high of 522.0M; above 406.5M on 09-01
Exhaustion	TD-9 (weekly / monthly / daily)	−3 / +1 / +2	Early counts, no exhaustion signal
Stretch	Z-score (weekly / monthly / daily)	+0.34 / +1.39 / +0.38	Not stretched
Key resistance	Closing highs / upper band	243.48–243.88 / 250.68	Breakout reference
Key support	10 EMA / Bollinger middle / 50 SMA	232.22 / 227.91 / 218.41	First downside references
Risk levels	Lower band / daily SuperTrend / weekly SuperTrend	205.13 / 195.10 / 172.93	Where a bearish case would be tested

Sentiment Analyst¶

Overall Sentiment: Neutral (Score: 5.0/10) Confidence: Low

Bottom line: no sentiment signal can be drawn for NBIS (Nebius Group N.V., NMS) for 2026-09-24 to 2026-10-01. The Neutral / 5.0 rating is a placeholder for missing data. It is not a measured read of the market. Every source was unavailable or skipped, so the trader should not treat this as a bullish, bearish, or balanced reading.

1. Source-by-source breakdown - Yahoo Finance news: The feed returned a placeholder saying it only serves recent items for this window. There were 0 headlines. The placeholder states this is not an absence of news for NBIS, so I cannot say what institutional framing, earnings, contract, or analyst headlines existed. - StockTwits: The feed returned a placeholder for the same reason. There were 0 messages, so I cannot compute a Bullish/Bearish ratio or a sample size. I have no read on retail positioning for $NBIS. - Reddit (r/wallstreetbets, r/stocks, r/investing): This source was skipped because the sentiment_include_reddit config is disabled. It was not queried, so I have no read on community discussion.

2. Cross-source divergences and alignments None can be assessed. With no source returning content, I cannot compare institutional news framing with retail sentiment.

3. Dominant narrative themes None can be identified from the evidence supplied. I have not inferred themes from outside knowledge about Nebius, such as AI-infrastructure or GPU-cloud demand, because the instructions limit me to the evidence in this prompt.

4. Catalysts and risks No catalysts or risks surfaced from the data. I cannot confirm the timing of upcoming earnings, product launches, financing events, competitive developments, or macro headlines for the period. Because the news feed was unavailable, there may be material events in the window that this report does not capture.

5. Data-quality caveats - All three sources are missing: two returned "unavailable" placeholders and one was disabled by config. - Confidence is low, which fits the rule for placeholder sources or fewer than 5 data points. - The downstream decision-maker should rely on fundamentals, technicals, and any other analyst inputs. If a sentiment view is needed, re-run with working news and StockTwits feeds, or with Reddit enabled.

Summary table

Signal	Direction	Source	Supporting evidence
News framing	Unknown	Yahoo Finance	Placeholder returned; 0 headlines; not evidence of no news
Retail Bullish/Bearish ratio	Unknown	StockTwits	Placeholder returned; 0 messages; no ratio computable
Community discussion	Unknown	Reddit	Skipped by config; not queried
Cross-source divergence	Not assessable	All	No source data available
Catalysts/risks	None identified	All	No evidence supplied
Overall	Neutral (placeholder, no data)	All	Score 5.0 reflects absence of data, not balanced sentiment

News Analyst¶

NBIS (Nebius Group N.V.) – News and Macro Report, week ending 2026-10-01¶

Data coverage¶

Source	Status
NBIS company news (9/24–10/1 and 9/1–10/1)	Unavailable. The Yahoo Finance vendor returned "only serves recent items". This is a tool limitation, not evidence that no NBIS news exists.
FRED macro series (fed funds, 10y, CPI, VIX)	Unavailable. The FRED_API_KEY is not set. I have no actual values for rates, inflation or VIX and have not estimated any.
Prediction markets (Fed cut, recession)	Withheld for 2026-10-01 to avoid look-ahead bias.
Global news (headline list)	Available. It gives headlines and links only, with no article bodies.

Everything below comes from headlines only. Figures such as "23%" are headline claims I could not verify in the article text.

Macro and market backdrop (from headlines)¶

Market tone, 10/1: Yahoo's live blog headline reads "Dow, S&P 500, Nasdaq stage comeback as Treasury yields fall, chip stocks gain." This suggests a risk-on bounce led by semiconductors, with yields falling. It follows a weaker stretch, since a "comeback" implies prior losses. Index levels and yield levels were not provided.
Fed and inflation: One headline reads "Chorus of Fed officials warn inflation is still too high, signaling more work to do on interest rates." The tone is hawkish, which is a headwind for long-duration growth stocks. A separate headline says silver gained "following the latest PCE report." I could not see the PCE figures, so I can't say whether the report was hot or cool.
Valuation and fragility warnings: Jeffrey Gundlach (MarketWatch) says the stock market is "a hollow tree that could be about to snap." This points to narrow leadership and fragility risk.
AI demand sentiment:
Accenture reportedly jumped 20–23% on record bookings, with a strong outlook for 2027. Headlines say this "dispels AI demand fears."
IBM rose about 5%, and Infosys rose about 8%.
IT services names also rallied: EPAM, DXC, EXL, Grid Dynamics, Concentrix, TaskUs.
Micron and Synopsys were named among stocks that explain the market's move.
Together these suggest the AI-adoption trade got a sentiment boost and that AI-linked hardware and semiconductor names (including Micron) are in focus. The effect on NBIS is inferred, not shown by any NBIS-specific data.
Commodities: Headlines point to strong September performance in metals, including silver and gold, with heavy junior-mining news flow. I have no price data.

Implications for NBIS¶

NBIS is an AI-infrastructure and GPU cloud company. The Communication Services classification doesn't match how it trades. Its behavior is tied to the AI capex cycle, Nvidia-linked sentiment, financing conditions and rates. Everything here is inference from the macro headlines.

Supportive:
Chip stocks are rallying and yields are falling.
The Accenture and IBM results ease AI-demand worries.
Risks:
Hawkish Fed commentary.
Gundlach's warning about fragile market breadth.
High-beta AI names tend to swing hard if sentiment turns.
NBIS typically funds its build-out with capital raises, so it is sensitive to equity and credit conditions. I could not verify any recent financing news.
Not checked: I had no NBIS-specific information on earnings dates, contracts with Microsoft or Meta, capacity updates, analyst actions or insider activity. Another source should fill these gaps before any decision.

Suggested follow-ups for the next analyst¶

Retrieve NBIS price action, volume and technicals, and any company news from a different vendor.
Pull actual yield, VIX, PCE and CPI data, and the Fed funds path, from a source that works.
Check upcoming catalysts: the Nebius earnings date, Nvidia and hyperscaler capex commentary, and the October jobs and CPI releases.

Summary table¶

Area	Finding	Source quality	Relevance to NBIS
NBIS company news	Not retrievable	Tool failure	Large gap
Equity market, 10/1	Rebound; yields falling; chips up	Headline only	Mildly positive
Fed	Officials say inflation is still too high	Headline only	Negative for high-multiple growth
PCE report	Released around 10/1; content unknown	Headline only	Unknown
Market structure	Gundlach warns of a "hollow" market	Opinion headline	Downside tail risk
AI demand	Accenture up 20–23% on record bookings; IBM up about 5%	Headline only	Positive for AI sentiment
Semiconductors	Chip stocks gain; Micron and Synopsys cited	Headline only	Positive read-through
Metals	Strong September; silver up after PCE	Headline only	Low
Rates, CPI, VIX values	Unavailable (no FRED key)	None	Cannot quantify
Prediction markets	Withheld by design	None	Cannot quantify

Bottom line: The data supports only a cautiously constructive AI and semiconductor sentiment backdrop, offset by hawkish Fed rhetoric and fragility warnings. There is nothing NBIS-specific, so this is not enough to support a trade view on its own.

Fundamentals Analyst¶

NBIS (Nebius Group N.V.) Fundamental Report, as of 2026-10-01¶

1. Scope and data limits¶

Profile data is unavailable. The get_fundamentals tool withheld market cap, valuation multiples, the 52-week range and TTM figures. The vendor only serves present-day values, which would leak information after the analysis date. I can't give P/E, P/S or EV/Sales from the tools, and I won't estimate them.
Latest reported period is Q2 2026 (June 30, 2026). Q3 2026 ended yesterday and has not been reported. No filings fell in the past week, so the weekly signal is mostly insider activity plus the Q2 fundamentals.
The identity matches the brief: Nebius Group N.V., NBIS. Nothing in the tool output contradicts it. The statements show a business that looks like an AI-infrastructure/GPU-cloud operator: heavy PP&E, large capex and large deferred revenue. That differs from the "Internet Content & Information" label.
Prices cited below are inferred from insider transaction prices. They are not market data.

2. Income statement: very fast growth, still operating at a loss¶

Quarter	Revenue ($M)	QoQ	Gross profit ($M)	Operating income ($M)	Op. margin	Net income ($M)	Diluted EPS
Q2'25	105.1	–	75.0	-111.2	-106%	584.4*	2.38*
Q3'25	146.1	+39%	103.2	-130.2	-89%	-119.6	-0.50
Q4'25	227.7	+56%	159.2	-250.0	-110%	-268.8	-0.99
Q1'26	399.0	+75%	295.2	-128.0	-32%	621.2*	2.11
Q2'26	582.3	+46%	448.7	-175.9	-30%	-190.4	-0.68

*The positive net income in Q2'25 and Q1'26 comes from non-operating securities gains ($622M and $781M), not from the business.

Key points: - Revenue grew about 454% year over year ($105M to $582M). It has risen sequentially every quarter. - Gross margin was about 77% in Q2'26 on the vendor's gross profit line (about 74% in Q1 and 70% in Q4'25). Reported cost of revenue excludes most depreciation, which is booked in operating expenses ($259.7M in Q2). Treat gross margin with caution. - Operating loss widened in dollars to -$175.9M from -$128.0M in Q1, even as margin held near -30%. R&D nearly tripled quarter on quarter ($67.4M to $191.0M). SG&A rose to $173.9M. - Normalized EBITDA is positive but small ($154M in Q2, $140M in Q1). It was negative in the three quarters before that. - Interest expense is rising quickly: $4.8M (Q2'25), $42.0M (Q4'25), $63.7M (Q1'26), $119.1M (Q2'26). Net interest was -$95M in Q2, and it will keep growing with the debt load. - Q2 net loss was -$190.4M. It included an $82.5M securities gain and a $13.7M tax provision. Earnings quality is low because the Q1 profit was almost entirely a one-off mark-to-market gain. - Share count: diluted average shares were 280.4M in Q2, up from 253M at year-end. The Q2 equity raise adds to this, so expect further dilution.

3. Balance sheet: large financing, large asset build¶

($M)	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26
Cash & equivalents	1,679	4,795	3,678	9,298	8,042
Restricted cash	74.5	107.1	6.8	n/a	830.3
Total assets	5,097	10,102	12,431	22,303	27,962
Net PP&E	2,067	3,815	6,472	8,398	14,900
Total debt (incl. leases)	1,224	4,569	4,973	9,496	10,171
Total liabilities	1,321	5,291	7,837	15,061	17,621
Stockholders' equity	3,776	4,811	4,594	7,241	10,340
Deferred revenue (current + non-current)	~19	~16	1,595	4,778	5,999

Liquidity: $8.04B of cash plus $830M of restricted cash. Working capital is $7.23B. Current liabilities are $2.39B, so the near-term ratio is comfortable.
Leverage: total debt is $10.17B. Long-term debt is $8.50B and lease obligations are $1.63B. Debt is about 0.98x equity. Total liabilities to equity is about 1.7x.
Net debt inconsistency: the vendor lists Net Debt at $503.6M. Total debt minus cash gives roughly $2.1B ($10.17B - $8.04B). The vendor figure may include investments or restricted cash. I'd verify it before relying on it.
Deferred revenue is about $6.0B ($5.0B non-current, $1.0B current). This points to large customer prepayments or contracted capacity, and it is a major source of cash flow. It is also a delivery obligation: if capacity is delayed, revenue recognition and customer relationships are at risk.
Asset base: Net PP&E rose from $8.4B to $14.9B in one quarter. Goodwill rose from $163M to $606M, and intangibles are $84M, which indicates acquisitions. Q1 and Q2 purchases of businesses were $170M and $81M.
Investments: $1.6B in available-for-sale securities, which produced the large gains in prior quarters. The investments are a source of earnings volatility, and they could be a source of liquidity.
Receivables: accounts receivable fell from $1.48B to $289M in Q2. That is a large collection that boosted operating cash flow.
Treasury/share structure: treasury shares were cancelled, so shares issued fell from 322M to 271.9M. Treasury stock fell to $782M. The share count is now 271.9M ordinary shares.

4. Cash flow: operating cash flow is positive, but free cash flow is deeply negative¶

($M)	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26
Operating cash flow	-171.6	-80.4	834.3	2,258.0	2,246.1
Capex	-510.6	-955.5	-2,056.0	-2,472.9	-5,657.4
Free cash flow	-682.2	-1,035.9	-1,221.7	-214.9	-3,411.3
Debt issuance	1,000	3,162.5	0	4,337.5	0
Equity issuance	0	1,150	0	2,001.8 (option/other)	2,846.7
Financing cash flow	1,000	4,200.6	106.4	6,295.5	2,864.9

Operating cash flow is driven by working capital, not earnings. The +$2.25B in Q2 included about $2.03B of working-capital inflow. The largest components were customer deferred revenue (about $1.2B in "other working capital") and collection of receivables (+$1.14B). SBC ($102.5M, up from $35.3M) and D&A ($294M) are non-cash add-backs.
Capex more than doubled quarter on quarter to $5.66B. Free cash flow was -$3.41B. TTM free cash flow across the four reported quarters is about -$5.88B.
Funding: Q2 was financed by $2.85B of equity issuance and no new debt. Q1 was financed by $4.34B of debt. The company has funded its build-out in alternating rounds of debt and equity. Cash fell by $535M in Q2 despite the raise. At this capex pace, expect more capital raising (convertibles, high-yield debt, asset-backed financing or equity).
Stock-based compensation is accelerating: $102.5M, about 18% of revenue.

5. Insider transactions (last ~6 months)¶

Past 30 days: - 2026-09-15: Director John Boynton sold 6,364 shares at about $208–217 (about $1.34M). - 2026-09-14: Officer Marc Boroditsky sold 7,000 shares at about $209 (about $1.46M). - 2026-09-01: CFO Maria Del Dado Alonso Sanchez sold 470 shares at $196 (about $92K). CEO, COO and the six non-employee directors each received 1,352 shares in stock grants.

Prior quarter: - Largest sale: Officer Andrey Korolenko sold 500,000 shares at $203.24 on 2026-05-13 (about $101.6M). He also sold about $8.0M on 2026-07-01, and about $3.5M and $2.7M in April and March. - CEO Arkady Volozh: sold 46,627 shares at $235.45 (about $11.0M) on 2026-07-01, and 33,358 shares (about $3.5M) on 2026-04-01. - CTO Danila Shtan: sold about $4.0M on 2026-07-01, $3.7M on 2026-06-04, and $1.3M-equivalent in March. - Director Charles Ryan: sold 50,000 shares at about $263–270 (about $13.3M) on 2026-08-14. - Director Boynton has sold around the 15^th of every month. Director Elena Bunina sold about $2–3M monthly in April and May. - Insider buying: there are no open-market purchases in this dataset. The only acquisitions are zero-cost stock awards, plus one general counsel grant (7,793 shares, about $1.7M on 2026-07-22).

Interpretation: - The sales are persistent and spread across most of the leadership team. Prices ranged from about $99 (end of March) to about $277 (June), and recent trades were around $196–217, so the stock has pulled back from the June–August highs. - The regular timing (1^st and 15^th of the month, same dates for several insiders) is consistent with scheduled plans (10b5-1) or tax-related sales on vesting dates. The tool does not confirm this. Even so, the absence of any buying is a mild negative signal.

6. Takeaways for traders¶

Positives - Revenue is growing about 450% year over year, with 46% sequential growth in Q2 after 75% in Q1. - Reported gross margin is about 77%, and normalized EBITDA is positive. - Operating margin improved from -110% (Q4'25) to about -30%. - Roughly $6B of deferred revenue implies strong contracted demand and visibility. - Liquidity is large: $8.0B cash plus $0.8B restricted, and $7.2B working capital. Equity base grew to $10.3B.

Risks - Free cash flow was -$3.4B in Q2 on $5.7B of capex, and capex is accelerating. The company needs ongoing external financing. - Debt is $10.2B, with interest expense of $119M a quarter and rising. Interest costs alone now consume most of the quarterly operating-level improvement. - Operating losses are still widening in absolute dollars. R&D jumped 183% quarter on quarter and SBC is accelerating. - Reported profits (Q1) came from investment gains and are not recurring. Q2 shows a -$190M loss. - Operating cash flow depends on customer prepayments and one-time receivable collections, so it may not repeat at this level. - Dilution is continuing, and Q2 had a $2.85B equity raise. - Insider selling is heavy and there is no buying. - Execution risk: delivering capacity to match about $6B of prepaid commitments.

Watch items - Q3 2026 results, due around the next reporting cycle. Look for revenue (a continued ~$800M+ run-rate would confirm trend), capex guidance, new financing and deferred revenue. - Any new debt or equity offering. Dilution and financing terms are the main near-term price catalysts. - The next insider filings around mid-October (the 15^th-of-month pattern). - Reconciliation of the net debt figure ($503.6M reported against about $2.1B computed).

7. Summary table¶

Category	Key data point	Read-through
Revenue (Q2'26)	$582.3M; +454% YoY; +46% QoQ	Very strong growth
Gross margin	~77% (excludes most D&A)	Strong, but definition-sensitive
Operating income	-$175.9M (-30% margin)	Improving margin, loss widening in dollars
Net income	-$190.4M (Q2); +$621.2M in Q1 from $780.6M securities gain	Low earnings quality
Normalized EBITDA	$154.2M	Positive but small
Interest expense	$119.1M (vs $4.8M a year ago)	Rising burden
Operating cash flow	$2,246M	Driven by deferred revenue and receivable collections
Capex	$5,657M (vs $2,473M in Q1)	Accelerating build-out
Free cash flow	-$3,411M	Heavy cash burn, TTM about -$5.9B
Cash	$8,042M + $830M restricted	Strong liquidity
Total debt	$10,171M (LT debt $8,499M, leases $1,625M)	High and rising
Equity	$10,340M	Equity raise of $2.85B in Q2
Deferred revenue	~$6.0B	Contracted demand and delivery obligation
Net PP&E	$14.9B (from $8.4B)	Fast asset build
Share count	271.9M ordinary shares	Ongoing dilution
Insider activity	Many sales (Korolenko $101.6M, Ryan $13.3M, Volozh $11.0M) and no open-market buys	Negative to neutral signal
Valuation	Not available from tools	Needs another source
Data gap	Q3'26 not yet reported; net debt field inconsistent	Verify before relying on it

II. Research Team Decision¶

Bull Researcher¶

Bull Analyst: # Bull Case for NBIS (Nebius Group N.V.)

I'll start with the facts and then take on the bear's best arguments before they're made.

1. The growth is real and accelerating¶

Revenue went from $105M in Q2'25 to $582M in Q2'26, up about 454% year over year. It has risen sequentially every quarter: +39%, +56%, +75%, +46%. Even the "slowest" recent quarter is a 46% sequential gain, which is a company doubling roughly every two quarters.
Operating leverage is showing up. Operating margin improved from -110% in Q4'25 to about -30% in the last two quarters, while revenue grew about 2.6x over that span. Normalized EBITDA is now positive ($154M in Q2), after being negative in the three quarters before Q1'26.
Gross profit was $449M on $582M of revenue (about 77%). I'll grant the bear that this excludes most depreciation. Even so, the unit economics of selling GPU capacity are clearly working at scale.

2. Demand is contracted, not hoped for¶

This is the most important number in the report. Deferred revenue is about $6.0B, up from ~$19M a year ago and $1.6B at year-end. It has risen every quarter ($1.6B, $4.8B, $6.0B). Customers are prepaying for capacity before it exists.

That changes how to read the capex. This isn't a speculative "build it and hope" story. The company is building against cash already in hand. Q2 operating cash flow was +$2.25B, and about $1.2B of the working-capital inflow was customer deferred revenue.

3. The balance sheet can fund the build¶

$8.04B in cash plus $830M restricted, and $7.23B of working capital against only $2.39B of current liabilities.
Q2 was funded with $2.85B of equity and no new debt. Investors are willing to fund this build at the current stock price, which is a signal in itself.
Equity rose to $10.3B, and debt-to-equity is about 0.98x, which is not extreme for infrastructure.
Net PP&E went from $8.4B to $14.9B in a single quarter, and it was nearly $2.1B a year ago. That capacity is largely not yet in the revenue line. Q2 revenue came from a far smaller asset base than the one now in place. If deferred revenue converts as delivered, the revenue catch-up is the thesis.

4. The tape confirms the fundamentals¶

NBIS is up about 128% since April 1 (101.95 to 232.28), and it's holding well above its 50-day SMA (218.41) and 200-day SMA (166.93).
SuperTrend is UP on the weekly, monthly and daily timeframes. The weekly stop is 172.93, with the close 34% above it. Nothing has flipped.
September made higher lows (199.54, then 207.37) after the August spike and fade. The stock absorbed a 277-to-199 round trip without breaking structure.
It isn't overheated. RSI is 52.8, the daily z-score is +0.38, and TD-9 counts are early. This is a consolidation, not a blow-off.
OBV was higher at the second test of ~243 (522.0M on 09-24, versus 469.7M on 09-08). That suggests accumulation across the September swings.

5. The macro backdrop is supportive at the margin¶

On 10/1 chips rallied and yields fell. Accenture's reported record bookings and IBM's move were framed as dispelling AI-demand fears. These are headline-level reads and not NBIS-specific, but the direction favors AI-infrastructure names.

Pre-empting the bear¶

"Free cash flow was -$3.4B." It was, because capex was $5.66B, a deliberate, contract-backed build. Negative free cash flow is what hypergrowth infrastructure looks like before the capacity comes online, and operating cash flow of +$2.25B shows the engine funds a large part of it.

"Interest expense is $119M a quarter and rising." That's fair, and it's the item I'd watch. But normalized EBITDA ($154M) already covers it, and EBITDA is growing with revenue while the $5.66B Q2 capex has yet to generate its return.

"Q1 profit was just securities gains." Agreed, and I'm not counting it. My case rests on revenue, margin trajectory and deferred revenue, not on the $621M headline.

"Dilution." Shares outstanding are about 271.9M, and the Q2 raise brought in $2.85B. The question isn't whether dilution happens but what the capital earns. If $14.9B of PP&E converts against $6B of prepayments, that dilution is cheap.

"Insiders are selling." True, and I won't spin it as buying. But the cadence is regular (1^st and 15^th of each month, the same dates across several insiders), which looks like scheduled plans or vesting-related sales. The tool doesn't confirm this. The dollar amounts are also modest relative to the stock's move from ~$99 to ~$277. The CEO, COO and all directors received stock grants on 09-01.

"ADX is 18.6, so it's choppy." Yes, the short term is range-bound at roughly 205–245. A range after a 128% rally, with the 50-day average rising underneath, is a base, and the trend-strength signal just hasn't confirmed yet. A close above 243.88 with volume opens 250.68, then 277.68.

"Gundlach says the market is hollow, and the Fed is hawkish." Those are macro risks for all high-beta growth. They argue for sizing the position, not for ignoring a company with $6B of prepaid demand.

Where I'm being straight about the gaps¶

Valuation isn't in my data. As a rough back-of-envelope (not a sourced figure), ~272M shares at ~$232 is around $63B. That's about 27x Q2's annualized revenue of ~$2.3B, which is rich. I expect the bear to lead with this. My answer is that the run-rate is moving fast and $6B of deferred revenue is already contracted, so the multiple should compress quickly if growth holds.
Q3 is unreported, and there's no NBIS-specific news or sentiment data this week. That's a data gap, not a negative.
The vendor's net debt figure ($504M) doesn't reconcile with debt minus cash (~$2.1B). Even the larger number is small against $14.9B of PP&E and $10.3B of equity.

What would prove me right or wrong¶

Right: Q3 revenue continuing toward the $800M+ range, deferred revenue still rising, and the next financing at acceptable terms.
Wrong: a close below 218.41 and then 205, a weakening deferred-revenue balance, delivery delays against prepaid capacity, or a costly financing that makes interest eat the EBITDA improvement.

So, bear: where do you want to start? My guess is valuation and financing risk. I'd like to hear how you handle $6B in customer prepayments and a revenue base that has grown about 5.5x in a year. Bull Analyst: # Bull Rebuttal: NBIS

You've sharpened this debate, and several of your points land. I'll concede those first, then show where your conclusion goes further than your numbers.

Where you're right¶

"The engine funds the build" was overstated. About $2.0B of the $2.25B operating cash flow was working capital, and the $1.14B receivables collection won't repeat. I'll retire that line.
Valuation is rich. At roughly $65B market cap and about 29x annualized Q2 revenue, there's no margin for error. My case is that run-rate revenue catches up, not that the stock is cheap today.
My 218.41 invalidation level was too tight. It's the 50-day SMA, inside one ATR of the close, so it's noise. A better line is a close below 199.54 (the September low), then the 195.10 daily SuperTrend stop. That matches the 2× ATR stop in the technical report.
Dilution is real. Diluted shares are up about 11% in two quarters.
Interest coverage is thin, and there's no insider buying. I'll treat the first as the main thing to watch and the second as a mild negative.
The macro read-through is weak. NBIS fell on 10/1, and the AI-demand headlines were about IT services. I won't lean on it.

Where your argument overreaches¶

1. "Operating leverage has stalled" misses SBC. The -32% to -30% margin includes SBC jumping from $35M to $102.5M. Adding back SBC, which is a real cost, so I'm only using it to see the cash-opex trend, the operating margin goes from about -23% to about -13% (-$92.7M on $399M, then -$73.4M on $582M). That assumes SBC sits in operating lines. The business is leveraging its cash costs while spending heavily on R&D and equity compensation.

2. Your "SBC is a likely add-back" worry isn't supported by the numbers. Operating income plus cash-flow D&A is about $118M (-$175.9M + $294M), already positive with no add-backs. Normalized EBITDA is $154M. If SBC were fully added back, you'd expect about $220M. The normalization looks modest. Your point that coverage is thin still stands: about $118–154M against $119M of interest. But much of that interest is carried on assets still under construction.

3. The "deceleration" is arithmetic. Sequential revenue additions were +$41M, +$82M, +$171M and +$183M. Hitting $800M in Q3 means about +$218M, and the dollar adds keep rising. Growth rates fall mechanically on a bigger base. If that +$180–220M cadence merely holds (an extrapolation, not guidance), revenue passes $1B a quarter around Q4. On today's ~$65B market cap, $4B annualized is about 16x. That's still not cheap, but it's a different picture from 29x.

4. Your deferred revenue "slowdown" is a lumpy-quarter comparison. Net increases were +$1.58B, +$3.18B and +$1.22B. Q1 was the outlier. Q2 is in line with Q4'25, and it's net of whatever was recognized as revenue, which is growing. Your "$16B of obligations vs. $8B cash" framing mixes two different things. Debt is repaid in cash with interest. Deferred revenue is settled by delivering capacity the company is building with that cash. Refund rights and penalties are unknown, and I agree that's the key diligence gap. But $5B being non-current is duration, which is visibility for a business whose main risk is demand. The $1.0B current portion isn't a revenue forecast either, since a large share of revenue isn't prepaid.

5. Your runway math is too pessimistic. - Liquidity: it ignores $1.6B of available-for-sale securities, on top of $8.04B cash and $0.83B restricted cash. - Capex: it assumes $5.66B a quarter continues. Capex was $2.06B, $2.47B, then $5.66B, which looks lumpy and delivery-driven. - Financing: the company has raised ahead of need ($4.3B of debt in Q1, $2.85B of equity in Q2), not at the last minute. - The $1.1B gap between PP&E additions and capex: debt rose about $0.7B with no new issuance, which is consistent with finance leases. That's an inference, but it suggests part of that gap is already in the $10.2B debt figure.

6. Even a raise isn't a thesis-breaker. A $3B raise at $232 would be about 12.9M shares, or about 4.7% of 271.9M. That's illustrative arithmetic, not a forecast. Funding contracted capacity at that cost is acceptable. The $4.85B of equity raised in Q1 and Q2 (the Q1 amount is labeled "option/other") came with the diluted count up 11%, while net PP&E went from $6.5B at year-end to $14.9B.

7. On the tape, your points are fair but partial. Lower closing highs and a weak ADX do argue for patience. Still, the stock is 57% above the July low (148.22) and 39% above the 200-day SMA, so "chosen start date" doesn't tell the whole story. OBV's give-back came on 11–15M-share sessions, far below the spike days, and OBV is still above its 09-01 level (406.5M). The weekly SuperTrend is a trailing stop, not a price floor, and I agree the weekly signal says little about near-term risk.

8. Insiders are neutral to mildly negative, not decisive. Sales cluster on the 1^st and 15^th, across prices from about $99 to $277. That's consistent with price-insensitive plans, though the tool doesn't confirm it. We also don't have insider holdings, so we can't say what fraction was sold. Korolenko's $101.6M sale at $203 came before the stock reached the high-$270s.

What we agree on¶

Your upgrade conditions are almost identical to mine: - Q3 revenue of at least $800M with operating margin better than -30%. - Deferred revenue still rising, with a net increase near or above Q2's $1.2B. - A financing without punitive terms. - A close above 243.88 on volume with ADX above 25.

So the debate comes down to Q3 execution and financing terms. If those arrive, you agree the thesis improves.

Bull bottom line¶

NBIS has revenue up about 454% year over year, about $6B of prepaid contracts, $14.9B of net PP&E mostly not yet in revenue, and a market that has funded each raise. The risks are real: a rich multiple, thin interest coverage, continuous dilution, and delivery risk on long-dated prepayments.

My stance is a constructive position sized for volatility: - Size: ATR is about 6.9% of price, so use a smaller position than conviction alone suggests. - Adds: add in tranches on a confirmed breakout above 243.88, not on hope. - Exit: invalidate on a close below 199.54, then 195.10, or on a falling deferred-revenue balance, delivery slippage or punitive financing.

I'd rather own the capacity catch-up with defined risk than short a company adding $180–220M of quarterly revenue and backed by $6B of prepayments. Bull Analyst: # Bull Closing Rebuttal: NBIS

You've pushed me to a narrower, more honest thesis. I'll concede what the numbers support, then show where your conclusion still goes further than your own data.

Where you're right¶

"In line" was too loose. Q2's +$1.22B deferred revenue add is about 23% below Q4'25's +$1.58B. Prepayment inflow isn't growing, and I'll treat that as a watch item.
Coverage is thin. Nothing in the data shows capitalized interest, so I can't lean on it. Coverage of about 1.0–1.3x stands.
Dilution is a recurring cost. Diluted shares rose from 253M to 280.4M, so about 23% annualized at that pace is fair arithmetic.
Stops don't protect against gaps. A +34% day and a -19% three-session slide are in the tape, and fundamental exits only show up quarterly. I'm dropping "defined risk" as a claim.
Adding at ADX 18.6 is whipsaw territory. I'll require ADX above 25 or a good Q3 print before adding.
The insider selling isn't bullish. My "$203 before the highs" example was selective. Insiders also sold near $99, before a 2.8x move, so their timing hasn't predicted anything in either direction. But there are no buyers, and I'll keep that as a mild negative.

Where you still overreach¶

1. The $800M bar doesn't need re-acceleration. Your argument treats dollar adds as a trend to extrapolate. The data suggests they follow the prior quarter's capex:

Quarter	Revenue add	Prior-quarter capex	Ratio
Q3'25	$41M	$511M	8.0%
Q4'25	$82M	$956M	8.6%
Q1'26	$171M	$2,056M	8.3%
Q2'26	$183M	$2,473M	7.4%

Q2 capex was $5.66B. Half the historical ratio (~4%) gives about $226M of adds, or roughly $808M. The full ratio would imply over $1B, which I don't underwrite.

This is four data points. Capex includes non-GPU items, lags can lengthen, and the construction-in-progress split is unknown. It's a pattern, not a forecast. It also implies revenue of only about 30% a year on each capex dollar, so payback depends on the gross margin holding. Q3's margin will test that. Even so, the "+7% step" extrapolation ignores that Q2's add came from capex deployed in prior quarters.

2. Your D&A and construction-in-progress arguments contradict each other. In point 1 of your last round, "$14.9B in place" isn't billable because much of it may be construction in progress. In point 2, depreciation steps up as though all $14.9B is in service at the old rate. Either it's in service and generating revenue, or it's not in service and isn't depreciating. The $81M D&A step-up and the "no revenue yet" case can't both be at full strength.

3. Prepayments are backed by built assets. You say the cash was spent and the obligation remains. That's what PP&E is. The $6.0B of deferred revenue is matched by $14.9B of net PP&E that is the delivery mechanism. That doesn't answer the refund-rights question, which I agree is open. But delivery risk is a different risk from refund risk. Net deferred revenue adds also understate gross billings, because recognition draws the balance down.

4. Dilution has to be measured against what it buys. Revenue per diluted share went from about $0.90 in Q4'25 ($227.7M / 253M) to about $2.08 in Q2'26 ($582.3M / 280.4M), 2.3x in two quarters against 11% more shares. I'll grant that per-share earnings are still negative, and that revenue per share only matters if margins follow. But "per-share value must compound over 20% to stand still" is already being met on the revenue line. Your 19.2M-shares-at-$148 point is the real risk: the funding window depends on the price. That's why I treat financing terms as a primary exit trigger.

5. Position size is the risk control. The stock fell 48% in six weeks. I'd size a position so a repeat of that is survivable, and I'd treat stops as a secondary tool.

Where we really disagree¶

Waiting for the technical trigger costs only about 5% (243.88 vs. 232.28). The real difference is the starter position ahead of the Q3 print. You say zero, because $800M is already priced in. I say a small one. Three things support that:

At ~$65B and a $778–800M Q3, run-rate sales are about $3.1–3.2B, so the multiple is about 20–21x, not 28x. That's your own "20x" figure.
Q3 ended 9/30, so the quarter's revenue is already earned. The unknown is the print, not the business.
Capacity is built, and prepayments are on the balance sheet.

I'd concede that without consensus data, "priced in" is judgment on both sides, and that the print is an event risk I can't hedge with a stop.

Bull bottom line¶

NBIS offers 454% revenue growth, $6.0B of prepaid contracts, $14.9B of mostly new capacity and revenue per share up 2.3x in two quarters. The costs are heavy dilution, thin coverage, a funding window tied to the share price and unknown contract terms.

Now: a small starter position, sized for a 50% drawdown.
Add: after a Q3 print at or above $800M with deferred revenue adds near $1.2B or more, or a close above 243.88 with ADX above 25.
Cut: on a deferred-revenue decline, delivery slippage, punitive financing, or a margin that fails to improve as depreciation rises.

You'd wait for proof. I'd hold a small position through it. If Q3 and the financing go well, this is the multiple that compresses fastest. If they don't, small size is what keeps the loss manageable. Bull Analyst: # Bull Closing Rebuttal: NBIS

Bull and bear now agree on the facts, the risks and the triggers. The only open question is whether a small position before Q3 is sensible. I'll concede what you've earned, then say why I still answer yes.

Where you're right¶

The payback math is the real long-term question. At about 8% of prior-quarter capex added to quarterly revenue, each capex dollar yields roughly 32% of annual revenue. That is about 3.1 years on revenue and about 4.1 years on 77% gross profit, before R&D, SG&A and interest. Useful life and contract pricing aren't in the data. I can't wave this away, and Q3 margin is where it first shows up.
Interest is the one cost that runs ahead of revenue. Depreciation starts when assets go into service, which is also when they bill. Interest does not wait. At $119M a quarter against $154M of normalized EBITDA, that mismatch is real.
"Q3 is already earned" cuts both ways. Costs, capex and any financing activity are already determined too, and we can't see them.
Sizing is survival, not edge. A position small enough to lose 50% only works if my judgment on the slope is right, and I have no consensus data to prove that.
Seniority is unknown. I don't know how creditors and prepaid customers rank against each other on the same assets.

Where I still disagree¶

1. Halving the ratio is a timing haircut, not a productivity collapse. Capex rose 2.3x in one quarter, from $2.47B to $5.66B. Nobody installs 2.3x the capacity in the same lag window, so more of it will land in Q4. That shifts revenue later without cutting what each dollar earns. The ratio held at 7.4–8.5% while capex went from $511M to $2.47B, which is a 5x range, so I would not read the Q2 dip to 7.4% as a trend. If Q3 comes in at $808M, the full ratio shows up in Q4 at about $1B. That is the scenario I'd call "priced to need" and the one that compresses the multiple. I don't underwrite it, but a small position is cheap exposure to it.

2. The print is a test of the slope, not the level. Your table shows the multiple moving only about one turn between a stall ($765M) and my base case ($808M). That treats Q3 as an end point. The market prices what Q3 implies for Q4. - A print near $808M means adds of about $226M, versus $183M last quarter. That would be the largest dollar add in the series and the first re-acceleration. It would validate the capex-lag model and point toward $1B. - A stall near $765M breaks the model.

The leverage is real in both directions. I'm judging that the lag table tilts the odds toward the first outcome, and I can't measure that.

3. Customers have put real money behind this. About $6.0B of deferred revenue sits against roughly $11.1B of trailing four-quarter capex, so customers have prefunded more than half of the build. I grant it is a liability. But customers don't put $6B on deposit for capacity they doubt will arrive. Total assets of $28.0B cover total liabilities of $17.6B about 1.6x, with $10.3B of equity beneath that. Seniority is unknown, but the cushion isn't thin.

4. The financing window is more open now than in July. The dilution math cuts both ways. $2.85B at $232 is about 12.3M shares, versus 19.2M at the $148 July low, which is 36% fewer shares for the same dollars. Liquidity of $8.04B cash, $0.83B restricted and $1.6B of available-for-sale securities means no forced raise this quarter. If a raise comes around the print, the stock being 57% above the July low helps. The risk is a price drop, which I've already counted as a primary cut trigger.

5. Revenue per share doesn't prove value, only that dilution is being outrun. I'm not claiming 28x trailing sales is cheap. Revenue per diluted share rose about 2.3x on 11% more shares. That says new equity is buying capacity that bills, which is the minimum a dilutive story needs.

Where we land¶

We agree on: - A rich valuation and thin coverage. - Recurring dilution, and stops that don't protect against gaps. - Unknown refund terms, customer concentration and in-service PP&E. - The same four upgrade triggers: Q3 revenue of at least $800M with operating margin better than -30%, deferred-revenue adds near or above $1.2B, non-punitive financing, and a close above 243.88 with ADX above 25.

You'd wait for proof and accept a 5–30% opportunity cost. I'd hold a small position through the print and accept the event risk.

Bull bottom line¶

NBIS has revenue up about 454% year over year, about $6B of prepaid contracts, $14.9B of net PP&E that is mostly not yet in revenue, and a market that has funded every raise so far. The costs are heavy dilution, thin interest coverage, a funding window tied to the share price, and contract terms we can't see.

Now: a small starter position, sized to survive another 48% drawdown like last summer's. The edge is a judgment on the slope, not a measured skew.
Add: after a Q3 print at or above $800M with deferred-revenue adds near $1.2B or more, or on a close above 243.88 with ADX above 25.
Cut: on a deferred-revenue decline, delivery slippage, punitive financing, or a margin that fails to improve as depreciation rises. Treat the 199.54 and 195.10 levels as intentions, not guarantees.

If Q3 and the financing go well, this is the multiple that compresses fastest. If they don't, small size is what keeps the loss survivable. I'd rather carry that defined-size risk through the print than wait on the sidelines for confirmation at a higher price. Bull Analyst: # Bull Closing Rebuttal: NBIS

Bear, we agree on the facts, the risks and the triggers, so this comes down to one decision. My answer is still a small starter position. You've earned several points, which I'll concede first.

Where you're right¶

Q3 is a partial test of revenue. If much of Q2's $5.66B capex lands in Q4, the full revenue proof comes with the Q4 print. Q3 only shows how much landed in-quarter.
A clean $808M doesn't move the multiple much. The re-rating needs the $1B+ path, which I said I don't underwrite.
The prepayment signal is ambiguous. A deposit can be a contractual condition for securing scarce capacity rather than a vote of confidence. Without customer concentration, refund rights or seniority, it could be single-name risk.
The 1.6x asset cover is a book number. GPU resale value and useful life aren't in the data.
My financing trigger fires late. Terms are public after the stock has reacted, so a stop or a "punitive financing" exit won't save the first move.
Liquidity runs about 1.7 quarters at the Q2 burn. That's $8.04B cash plus $1.6B available-for-sale securities against roughly $5.5B of burn. A raise before Q4 is likely.
My edge is a judgment, not a measurement. I can't price a defined-loss structure without options data, and I'll grant that one may fit better than shares if someone wants this exposure with capped risk.

Where I still disagree¶

1. Q3 isn't one-directional on costs. You say it can disappoint on costs without confirming the revenue slope. It can also surprise positively on deferred-revenue adds, margin and capex without confirming the slope. Revenue is also not entirely muddy. A print near or above $808M would be the first re-acceleration in dollar adds. Only a result between a stall and my base case is ambiguous.

2. Interest looks closer to a plateau than a runaway, unless new debt is added. - Interest went from $63.7M to $119.1M because Q1's $4.34B debt raise paid a full quarter in Q2. - Total debt rose only about $0.7B in Q2. - Equity funded Q2, so debt/equity fell from about 1.31x ($9.5B / $7.2B) to about 0.98x. - $119M on roughly $9.8B of average debt is about 4.8% annualized. That implies a modest average cost, though I can't see the debt mix or capitalized interest. - If the next raise is equity again, the interest line grows slowly and the pain is dilution. If it's debt, interest steps up again. Financing mix is the variable to watch.

3. The drift in the lag ratio is small. It went 8.3% to 7.4% on the last step, after holding 8.0–8.6% while capex rose 5x. I wouldn't call that a trend yet. Q3 will add a fifth data point.

4. The stock's rise already reflects growth that was delivered. I agree. A rise of 57% from the July low reflects a recovery from a 48% drawdown as well as new information. Neither of us can separate the two from this data.

Where we land¶

We agree on the valuation, thin coverage, recurring dilution, unknown contract terms, the gap-risk caveat on stops, and the four triggers: - Q3 revenue of at least $800M with operating margin better than -30%. - Deferred-revenue adds near or above $1.2B. - Non-punitive financing. - A close above 243.88 with ADX above 25.

The only open question is whether to own a small position through the print.

Bull bottom line¶

NBIS has revenue up about 454% year over year, about $6B of deferred revenue, $14.9B of net PP&E, and a market that has funded each raise so far. The costs are heavy dilution, thin interest coverage, a funding window tied to the share price, and contract terms we can't see.

Now: a small starter position, sized to survive another 48% drawdown. The case rests on judgment about the revenue slope, not a measured edge. If gap risk is unacceptable, waiting for the triggers is a defensible choice, and I'd say so.
Add: after a Q3 print at or above $800M with deferred-revenue adds near $1.2B or more, or on a close above 243.88 with ADX above 25.
Reduce or exit: on a deferred-revenue decline, delivery slippage, punitive financing, or margin that fails to improve as depreciation rises. Because those signals arrive late, the position size has to absorb the first move.

You'd wait for proof and pay for it with some of the re-rating if the print is clean. I'd carry a small position through the event and accept that risk. Both are reasonable, and the Q3 print, financing terms and deferred-revenue balance will show which was better.

Bear Researcher¶

Bear Analyst: # Bear Case for NBIS

Bull, the growth is real. $582M of revenue, up 454% year over year, isn't in dispute. My disagreement is over what that growth costs, who is paying for it, and what a ~$63B price already assumes. Several of your load-bearing claims don't hold up against your own numbers.

1. "The engine funds a large part of the build" is wrong¶

You cite +$2.25B of operating cash flow. About $2.03B of that was working-capital inflow: roughly $1.2B of new customer prepayments and a $1.14B receivables collection (AR fell from $1.48B to $289M, which can't repeat). Strip those out and underlying operating cash flow is about $0.2B against $5.66B of capex, or about 4%. The rest came from prepayments, a one-time collection and $2.85B of new equity.

2. Deferred revenue is weaker than you present it¶

It's a liability. Debt of $10.2B plus $6.0B of deferred revenue is about $16B of obligations against $8.0B of cash. If you treat prepayments as customer financing, net obligations are roughly $8B, not the vendor's $0.5B or even $2.1B. This is my framing. Refund rights and delivery penalties aren't in the data.
The inflow is slowing. Quarterly increases were +$1.58B (Q4'25), +$3.18B (Q1'26) and +$1.22B (Q2'26). New prepayments fell about 62% quarter on quarter in the same quarter capex more than doubled. "Risen every quarter" is true, but the pace isn't.
It's mostly not near-term revenue. $5.0B of the $6.0B is non-current. Only about $1.0B is slated for the next 12 months, against a $2.3B annualized run-rate. The "catch-up as it converts" story is multi-year.
We're missing key terms. The data has no customer concentration, pricing or contract tenor. Those decide whether prepayments are an annuity or a delivery risk.

3. Operating leverage has stalled¶

Operating margin went from -32% in Q1 to -30% in Q2, which is flat. The dollar operating loss widened 37% (-$128M to -$176M). R&D rose 183% quarter on quarter and SBC went from $35M to $102.5M.
The Q2 net loss of -$190M includes an $82.5M securities gain. Excluding it, the loss is roughly -$273M.
"EBITDA covers interest" leaves about $35M ($154M vs. $119M), before taxes and before $5.66B of capex. The report doesn't define "normalized," and SBC is a likely add-back. Interest expense was $4.8M a year ago.
You say the new capacity isn't in revenue yet. It isn't in depreciation yet either. Q2 D&A was $294M on an average PP&E base of roughly $11.7B. At that rate, $14.9B would be about $375M a quarter, which is my extrapolation, not a reported figure. PP&E is already 6.4x annualized revenue.

4. The funding treadmill¶

Cash is $8.04B. At the Q2 capex pace and about $0.2B of underlying operating cash flow, that's roughly a quarter and a half of runway. TTM free cash flow is about -$5.9B. Total liabilities went from $7.8B to $17.6B in six months.
"No new debt in Q2" is incomplete. Total debt including leases still rose from $9.5B to $10.2B. The tool doesn't say why, so it is probably leases or other non-cash items.
"Investors will fund this at the current price" is circular. The build is financed by the stock price, and the stock price is justified by the build. If the stock slips, the next raise gets more expensive just as the capex bill arrives.
PP&E rose $6.5B in one quarter, more than the entire year-end balance ($6.47B). That implies about $1.1B of additions beyond cash capex, which is cash still to go out. The tool doesn't break this down.

5. Valuation is the problem¶

Your ~$63B uses 271.9M shares. The Q2 diluted average was 280.4M, which gives about $65B, and about $67B of EV. That's roughly 29x annualized Q2 revenue. This is my arithmetic, because the tools returned no valuation data.
Your own bar of ~$800M for Q3 is +37% quarter on quarter. That would be a third straight deceleration (75%, 46%, 37%), and it would still leave the stock near 20x annualized sales. That's a steep price for a -30% operating margin and -$3.4B of quarterly free cash flow.
Diluted shares are up about 11% in two quarters.
"The multiple compresses if growth holds" is just another way of saying it's priced in. The bull case needs growth, on-time delivery and cheap financing all at once.

6. The tape doesn't confirm the fundamentals¶

"Up 128% since April 1" is a chosen start date. The stock is 19% below its June closing high of 286.69.
Closing highs have stepped down: 286.69, 277.68, 243.88, 243.48. Higher September lows plus lower highs is compression, not a confirmed base. ADX is 18.6 and falling, so there is no trend.
The path was -48% in six weeks, +87% in about two and a half weeks, then -19% in three sessions. ATR is 6.9% of price. That behavior looks driven by flows and financing expectations, not by a stable annuity.
SuperTrend being "UP, 34% above the stop" means the weekly signal won't flip until about 25% is lost.
Your invalidation level of 218.41 is 6% below the close, less than one ATR (16.07). It sits inside daily noise.
OBV has already given back 38M of the "accumulation" (522.0M to 484.3M) since 09-24. The last four sessions traded on 11–15M shares, and MACD has slipped from 4.78 to 4.52.
On 10/1, the day of the "chips rally, yields fall" headline you cite, NBIS fell about 1.5% (235.88 to 232.28) and closed below its 236.18 open. The AI-demand read-through also came from IT-services names (Accenture, IBM, Infosys), and the news report itself calls the NBIS link an inference. The same news set carries hawkish Fed commentary and Gundlach's warning. For a company that needs a multibillion-dollar raise every quarter or two, rates and risk appetite are the cost of financing, not just a sizing issue.

7. Insiders¶

There are no open-market purchases in the dataset, including through the drawdown to 148. The largest sales were $101.6M (Korolenko, 5/13), $13.3M (Ryan, 8/14, near $270) and $11.0M (Volozh, 7/1). The 09-01 grants were 1,352 shares each, roughly $270K apiece, which is compensation, not conviction. A 10b5-1 explanation is plausible, but the tool doesn't confirm it. Either way, the people closest to the delivery schedule are sellers and none are buyers.

Gaps and what would change my mind¶

There is no sentiment data and no NBIS-specific news this week. Neither side can claim support from them. Q3 ended 9/30 and is unreported.

I'd turn more constructive on: - Q3 revenue at or above $800M with operating margin better than -30%. - Deferred revenue growing by more than the Q2 increase (~$1.2B). - A financing without heavy dilution or punitive terms. - A close above 243.88 on volume with ADX above 25.

Bottom line¶

NBIS is a genuinely fast-growing business. It is also externally financed, still loss-making at the operating line, and priced at roughly 20–29x run-rate sales. It depends on an equity market that stays open and on flawless delivery against long-dated prepayments. Growth being real doesn't make the price right. At ~$232, with a daily range near 7% and a likely raise ahead, I see the risk/reward as unfavorable. If you do own it, size for the volatility. Bear Analyst: # Bear Rebuttal: NBIS

You conceded the engine-funds-the-build claim, the rich valuation, the too-tight stop, the dilution, the thin coverage and the weak macro read-through. What's left is a "constructive, sized for volatility" stance that depends on Q3 going well. Several of your counters are still too generous.

Where you're right¶

Your SBC arithmetic checks out: -23% to -13% ex-SBC.
Operating income plus D&A (~$118M) against normalized EBITDA ($154M) suggests the normalization isn't a full SBC add-back.
I left out the $1.6B of available-for-sale securities, which adds liquidity.
Capex has been lumpy.
Growth rates do fall mechanically on a larger base.

Where it still doesn't hold¶

1. The $800M bar needs re-acceleration in dollar adds. - Sequential adds were +$41M, +$82M, +$171M and +$183M. "Keep rising" is true, but the last step was +$12M, or +7%. - At a +7% step, Q3 is about $778M, short of the bar we both set. Reaching $800M needs +$218M, a 19% step-up from a quarter where the add barely moved. - Your best answer is the PP&E that isn't in revenue yet. That's fair, but the data doesn't split in-service assets from construction in progress. "$14.9B in place" doesn't mean $14.9B of billable capacity. - Your Q4 ~$1B and 16x run-rate scenario is the case the price already needs, not upside. I have no consensus data, but at 29x trailing run-rate I'd assume it's priced in.

2. SBC and D&A. - The SBC math works, but SBC tripled in one quarter, from $35M to $102.5M. That's 17.6% of revenue, up from 8.8%. - It's paid in shares, so it moves cost from the P&L to the share count. That's the same 11% dilution you already conceded. - On my D&A extrapolation (~$375M vs. $294M, not a reported figure), the step-up is about $81M. An $800M quarter at ~77% gross margin adds about $168M of gross profit, so depreciation alone could absorb roughly half of it. Operating leverage depends on R&D and SG&A staying flat after R&D rose 183% last quarter. - On interest "carried on assets under construction": nothing in the data shows capitalized interest. If interest is being capitalized, it isn't in the $119M expense, so true interest cost is higher than the P&L shows and will hit earnings as assets go into service. Either way, coverage is about 1.0–1.3x before taxes and before $5.66B of capex.

3. Deferred revenue and "contracted demand." - Q2's +$1.22B versus Q4'25's +$1.58B is about 23% lower. That isn't "in line." - You said a large share of revenue isn't prepaid, which cuts against "demand is contracted, not hoped for." Your own $4B annualized scenario implies next-year revenue of roughly $4B or more, against $1.0B of current deferred revenue. So roughly a quarter is visible as prepaid. The rest may be contracted pay-as-you-go, but we can't see it. - You agree refund rights and penalties are the key diligence gap, yet you're sizing a position without them. The prepayments have also largely been spent. The cash went into capex and the delivery obligation remains.

4. Dilution is a per-quarter cost. - Your 4.7% is per raise, but the company has been raising about once a quarter. Diluted shares are up 11% in two quarters, about 23% annualized if that pace holds. - Per-share value has to compound over 20% a year just to stand still. - "Raised ahead of need" was easy at a stock up 128%. The same $2.85B is about 12.3M shares at $232 and about 19.2M at the July low of $148, or 56% more shares. The funding window is tied to the price, and the price fell 48% in six weeks last summer.

5. "Defined risk" is overstated. - Your stop at 199.54 is 14% below the close. In August the stock fell 19% in three sessions (277.68 to 223.90) and jumped 34% in one day (193.23 to 259.20). - A close-based stop can be gapped through. Financing terms and delivery slippage also arrive as discrete events, not as orderly closes. - Your fundamental exits (deferred revenue, delivery) are only visible at quarterly reports. - Adding on a breakout above 243.88 with ADX at 18.6 is the whipsaw zone. The technical report itself says trend signals are less reliable below ADX 25.

6. Insiders. "Korolenko sold at $203 before the highs" is selective. Volozh sold at $235 and Korolenko about $8M on 7/1, ahead of a 37% drop to $148. Ryan sold at $263–270 on 8/14, right at the August top. These are probably scheduled plans, so I'm not resting the case on it. Still, no insider bought at $148.

Where we land¶

We agree on the triggers: - Q3 revenue of at least $800M with operating margin better than -30%. - Net deferred revenue growth of about $1.2B or more. - A financing without punitive terms. - A close above 243.88 on volume with ADX above 25.

The disagreement is timing. You'd own it before the evidence. I'd wait. If Q3 hits $800M, it's what ~29x already assumes. If dollar adds stall near $180M, deferred revenue adds shrink again, or the raise is large, there's no cushion in the multiple. Without consensus data this is judgment, not a measured skew, but it's the asymmetry I see.

Bear bottom line¶

NBIS is growing fast, but the growth is externally financed. Operating income is still negative. Roughly 23% annualized dilution is in the run-rate. Coverage is thin. The contract terms that matter are unknown. A ~$65B market cap leaves little room for any of that to disappoint.

Stance: avoid or underweight ahead of Q3 and the next financing. Paying more after confirmation is a reasonable price for removing gap risk.
If you own it: use your stops, but treat them as intentions, not guarantees, given the gaps above.
What would change my mind: the four triggers above, plus disclosure of refund and penalty terms, customer concentration, and the in-service share of PP&E. Bear Analyst: # Bear Closing Rebuttal: NBIS

Bull, your closing narrowed this to one question: whether to hold a small starter position before the Q3 print. I'll concede what you earned, then explain why the starter position still doesn't follow.

Where you're right¶

The capex-lag table checks out. The ratios of revenue add to prior-quarter capex are 8.0%, 8.5%, 8.3% and 7.4%. That is a better model than my "+7% step" extrapolation, so I'm retiring $778M as a base case.
My D&A and construction-in-progress points were in tension. I can't claim full depreciation and no billable capacity at once. The better framing is a bracket. If the assets are in service, D&A rises and revenue should follow. If they're construction in progress, D&A doesn't rise yet, but neither does revenue. Both branches cost something.
Gross billings exceed the net deferred-revenue add. Recognition draws the balance down, so the $1.22B understates what customers paid.
Delivery risk and refund risk are different. They are linked, though, because a delivery failure is what triggers refund or penalty rights.
Waiting can cost more than 5%. If the print gaps up, I'd miss a lot more than the distance to 243.88. I accept that.

Where it still doesn't get you to a starter position¶

1. Your model reaches $800M only by breaking itself. - At the full historical ratio, Q3 revenue is about $1.03B, which you said you don't underwrite. - To land at ~$808M you halve the ratio. Halving means either capex earns half as much or it arrives later. - Either way, interest ($119M a quarter and rising) and depreciation start on schedule while revenue doesn't. - Even at 8%, each capex dollar yields about 32% of annual revenue. That is about 3.1 years of payback on revenue and about 4.1 years on gross profit at 77%. This is before the $365M a quarter of R&D and SG&A. Useful life isn't in the data. - The last three readings (8.5%, 8.3%, 7.4%) already drift down, and this is four data points.

2. The print barely moves the multiple. This is illustrative arithmetic on my ~$65B figure, with no consensus data.

Q3 revenue	Scenario	Annualized	Market cap / run-rate
~$765M	Dollar adds stall at +$183M	$3.06B	21.2x
~$808M	Your half-ratio case	$3.23B	20.1x
~$1.03B	Full ratio	$4.1B	15.8x

Between "adds stall" and your base case, the multiple moves about one turn. Revenue therefore isn't what decides the reaction. These are: - deferred-revenue adds - capex and financing - margin after depreciation

Those are the items you called unknown and listed as your exits. A starter position ahead of the print bets on a number with little price leverage while exposed to the ones with a lot. Only the $1B+ case re-rates the stock, and you don't underwrite it.

3. "Q3 is already earned" cuts both ways. - The costs and balance-sheet outcomes are also already determined, and we can't see them. - Our news tool returned nothing on NBIS, so we can't rule out a Q3 raise or other event. - The people who know the answer are insiders, and the latest filings (9/1, 9/14, 9/15) show sales, not purchases. These are probably scheduled plans, as I've said, so I'm not resting on it.

4. Revenue per share is the same growth restated. - Annualized Q2 revenue per diluted share is about $8.31 ($582.3M × 4 / 280.4M), and $232.28 is about 28x that. - The stock is up 128% since April 1, and revenue per share is up 2.3x since Q4'25. The windows differ, but the market has largely paid for that growth already. - EPS was still -$0.68 in Q2, and that includes an $82.5M securities gain.

5. "Backed by built assets" doesn't settle it. - The same $14.9B of PP&E sits behind $10.2B of debt, $6.0B of customer money and the equity base. - Customers and creditors are looking at the same assets, and we don't know seniority or refund terms. - A liability matched by an asset is still a liability.

6. Sizing addresses survival, not edge. - A position small enough to lose 50% is small enough that being right barely matters. Expected value still has to be positive at 28x trailing sales. - You dropped stops because of the +34% and -19% moves. The same moves apply to the cost of waiting. If a good print gaps up 20–30%, I miss it. - With revenue outcomes moving the multiple by about a turn, I judge paying up after confirmation worth it. That is judgment, not a measured skew.

Where we land¶

We now agree on most of the case: - Valuation is rich, and coverage is thin at about 1.0–1.3x. - Dilution recurs, and stops aren't guarantees. - Contract terms, customer concentration and the in-service share of PP&E are unknown. - The upgrade triggers are the same on both sides: - Q3 revenue of $800M or more with operating margin better than -30%. - Deferred-revenue adds near or above $1.2B. - Non-punitive financing. - A close above 243.88 with ADX above 25.

The only live dispute is whether to own a small position before those arrive.

Bear bottom line¶

NBIS is a real, fast-growing business, and the bull has argued it honestly. But it is externally financed, still loss-making at the operating line, and priced near 28x trailing and about 20x forward run-rate sales. Its own best capex model reaches the bar only if capital productivity falls.

Stance: no position ahead of the Q3 print and the next financing. Revisit on confirmation.
What would change my mind: the four triggers above, plus disclosure of refund and penalty terms, customer concentration and construction-in-progress.
What I'm giving up: the first 5–30% of a re-rating if the print is clean. That is the price of avoiding a miss at 20x+ run-rate sales with a raise still ahead.
If you hold anyway: keep it small, treat stops as intentions rather than guarantees, and let Q3 deferred revenue, capex and financing terms decide whether it grows. Bear Analyst: # Bear Closing Rebuttal: NBIS

Bull, this is the narrowest the debate has been. We agree on the facts, the risks and the triggers. The only dispute is whether to own a small position before the Q3 print. You also said the edge is "a judgment on the slope, not a measured skew." I think that sentence settles the question.

Where you're right¶

Halving the ratio can be a timing effect. Capex went from $2.47B to $5.66B in one quarter, and it's unreasonable to expect all of it to be installed in one lag window. I'm retiring "capital productivity falls" as the only reading.
The ratio held at 7.4–8.5% through a 5x capex range. One 7.4% reading isn't a trend.
The financing window is better than in July. The same $2.85B costs 12.3M shares at $232 versus 19.2M at $148. The cash balance means no forced raise this quarter.
Total assets of $28.0B cover total liabilities of $17.6B about 1.6x. That's a real cushion on paper.
Revenue per share is up 2.3x on 11% more shares. I'll grant that dilution is being outrun at the revenue line.

Where it still doesn't justify a position before the print¶

1. Your timing argument pushes the proof out a quarter, which supports waiting. - If Q2's $5.66B lands mostly in Q4, the "priced to need" ~$1B quarter shows up in the Q4 print, around February. It does not show up in Q3. - Q3 would then be a lagged, partial quarter. Its answer to the question you care about, what each capex dollar earns, would be muddy. - What Q3 does reveal immediately is the cost side: deferred-revenue adds, margin after depreciation, financing and capex. Those are the items you named as exits. - So the print can disappoint on costs without being able to confirm the revenue slope. A position held through Q3 takes the downside of that mismatch and gets only partial credit for the upside. - A longer lag also means the cash is out the door and interest runs at $119M a quarter while revenue waits. You conceded that interest is the one cost that doesn't wait.

2. "A test of the slope" is asymmetric at ~28x trailing sales. - A $765M stall breaks the model, and the stock reprices hard. We agree on that. - A $808M print is the first re-acceleration, but it's also the number the stock has been climbing toward. NBIS is up 57% from the July low in two months, and 128% from April. - Your own table shows a clean hit moves run-rate sales from 21.2x to 20.1x. The market has to believe the $1B case, which you say you don't underwrite. - You called the stock "cheap exposure" to the $1B scenario. That scenario isn't your base case, and the exposure comes with a 6.9% daily ATR and a precedent of -48% in six weeks. If someone wants cheap upside exposure to an event they don't underwrite, a defined-loss structure fits better than shares. I have no options pricing in the data, so I can't say whether that's economical here.

3. Customer prepayments are funding, and funding terms matter. - $6.0B against $11.1B of trailing four-quarter capex does mean customers have prefunded more than half the build. It can also mean the build depends on customers financing it. - "Customers don't put $6B on deposit for capacity they doubt will arrive" assumes the deposit is a vote of confidence. It could equally be a contractual requirement to secure scarce capacity. - We have no customer concentration, refund rights or seniority. If one or two counterparties hold most of the $6.0B, this is single-name risk, not a diversified demand signal. - The 1.6x asset coverage includes $8.0B of cash that is being spent, and $14.9B of GPU-heavy PP&E carried at book. Recoverable value depends on useful life, resale value and technology turnover, and none of that is in the data. - The cushion also shrinks if capex continues at anything like the Q2 pace.

4. The financing window depends on the price, and your cut trigger fires too late. - Liquidity is $8.04B of cash plus $1.6B of available-for-sale securities. The $0.83B of restricted cash isn't usable. Against roughly $5.5B of Q2 burn (capex less the ~$0.2B of underlying operating cash flow), that's about 1.7 quarters if capex stays at the Q2 pace. You say it's lumpy, which is fair, but it could also stay high. - A raise before Q4 is likely. The price at that moment sets the dilution. - You listed "punitive financing" as a cut trigger. By the time terms are public, the stock has typically already reacted. The cut happens after the loss. - The price has swung 19% in three sessions and 34% in one. It isn't a stable base for funding $5B+ a quarter.

5. You've admitted the edge isn't measured. - Position size addresses survival, not expected value. You said so yourself. - Your case reduces to "the lag table tilts the odds toward the good outcome," and you say you can't measure that. It's four data points, the ratio has drifted from 8.5% to 7.4% in the last two, and the capex-to-revenue link includes non-GPU items. - Revenue per share rising 2.3x measures growth already delivered. At about $8.31 of annualized revenue per diluted share, $232 is ~28x, while EPS is still -$0.68 including an $82.5M securities gain. - Without that gain, the net loss is about -$273M. Insiders have no open-market buys, even at $148. That's likely scheduled selling and not decisive, but it also isn't corroboration.

Where we land¶

We agree on: - A rich valuation, thin interest coverage (about 1.0–1.3x) and recurring dilution. - Stops that won't protect against gaps. - Unknown refund terms, customer concentration and in-service PP&E. - The same four triggers: Q3 revenue of at least $800M with operating margin better than -30%, deferred-revenue adds near or above $1.2B, non-punitive financing, and a close above 243.88 with ADX above 25.

The only difference is order. You'd hold a small position through the event. I'd wait for it.

Bear bottom line¶

NBIS is a real, fast-growing business, and you've argued the bull case honestly. But the company is externally financed, still loss-making at the operating line, and priced near 28x trailing and about 20x forward run-rate sales. The next proof of its capex returns comes in the Q4 print. The Q3 print mostly tests costs, funding and margins.

Stance: no position ahead of the Q3 print and the next financing. Revisit when the triggers are met.
What I'm giving up: some of a re-rating if the print is clean. I accept that cost to avoid gap risk and a likely raise at 20x+ run-rate sales.
If you hold anyway: keep it small, treat 199.54 and 195.10 as intentions and not guarantees, and let Q3 deferred revenue, capex and financing terms decide whether you add.
What would change my mind: the four triggers above, plus disclosure of refund and penalty terms, customer concentration, and the in-service share of PP&E. Bear Analyst: # Bear Final Rebuttal: NBIS

Bull, you've conceded most of what matters. The prepayment signal is ambiguous, the 1.6x asset cover is a book number, the financing trigger fires late, a raise before Q4 is likely, and the edge is judgment rather than measurement. What's left is whether your three remaining objections change the decision.

Where you're right¶

Q3 can surprise on the upside too. Strong deferred-revenue adds, better margin or lower capex would all be good news. I accept that.
Interest looks closer to a plateau if no new debt arrives. $119M on about $9.8B of average debt is roughly 4.8% annualized, and the $63.7M-to-$119.1M jump mostly reflects Q1's debt raise paying a full quarter.
One 7.4% reading isn't a trend, and I can't separate recovery from re-rating in the 57% bounce off the July low.
Waiting costs something. If the print is clean and the stock gaps, I give up part of that move.

Where it still doesn't get you to a position¶

1. Your lag model is hard to falsify with Q3. - If Q3 revenue is near $808M, the model is validated. - If it comes in lower, that's timing, because Q2's $5.66B lands in Q4. - Both outcomes fit the thesis, so Q3 can't clearly refute it. - A miss on costs, such as deferred-revenue adds, margin after depreciation or capex, has no such escape hatch. - The proof you want arrives with the Q4 print, which supports waiting.

2. The low implied interest rate cuts two ways. - A 4.8% average cost on $9.8B of debt and leases is either cheap paper or capitalized interest. The data doesn't say which, and both are inferences. - If it's low-coupon convertible debt, the cost shows up as dilution later. - If interest is being capitalized, the P&L understates the true cost, and it will hit earnings as assets enter service. - Debt-to-equity fell to 0.98x because of a $2.85B equity raise, not because the obligations shrank. You said it yourself: if the next raise is equity, "the pain is dilution." That is the same cost, paid in shares instead of interest.

3. The raise is the nearest catalyst, and your protections don't cover it. - Liquidity is about $9.6B ($8.04B cash plus $1.6B available-for-sale securities) against roughly $5.5B of Q2 burn, or about 1.7 quarters at that pace. - Capex may be lumpy, but nothing in the data says it will fall. - A raise could land before or after the print. Terms become public after the stock has reacted, and a position sized for a 48% drawdown only absorbs the loss. It doesn't create an edge. - I'd also note a judgment I can't prove from this data: companies tend to raise into strength, and the stock sits 57% above its July low.

4. The price already pays for the growth. - Annualized revenue per diluted share is about $8.31, so $232.28 is about 28x. - Operating margin is still -30%, and EPS was -$0.68 even with an $82.5M securities gain. - A clean $808M moves run-rate sales from 21.2x to 20.1x, and you agreed it doesn't re-rate the stock. Only the $1B+ path does, and you don't underwrite it. - You called the starter position "cheap exposure" to a scenario that isn't your base case. It comes with a 6.9% ATR and a -48% precedent. If someone wants that exposure with capped loss, a defined-risk structure fits better than shares. I have no options data, so I can't say whether that's economical.

5. The unknowns that matter are still unknown. - We don't have customer concentration, refund rights, seniority against $10.2B of debt, or the in-service share of PP&E. - Insiders show no open-market buying, even at $148. That's likely scheduled selling and not decisive, but it isn't corroboration either. - Sizing for survival is sensible, but it isn't a reason to take the risk.

Where we land¶

We agree on the facts, the risks, the four triggers, and that waiting is defensible. Here is what separates us: - You: hold a small position through the print because the lag table tilts the odds. - Me: the table is four data points, the Q3 test is lopsided against the bear case, and the real revenue proof comes in Q4. A raise is likely first, so I'd wait.

Bear bottom line¶

NBIS is a real, fast-growing business. It is also externally financed, loss-making at the operating line, diluting at about 23% annualized, and priced near 28x trailing and about 20x forward run-rate sales.

Stance: no position ahead of the Q3 print and the next financing.
What I'm giving up: part of a re-rating if the print is clean, which I accept to avoid gap and financing risk.
What would change my mind:
Q3 revenue of at least $800M with operating margin better than -30%.
Deferred-revenue adds near or above $1.2B.
Non-punitive financing.
A close above 243.88 with ADX above 25.
Disclosure of refund terms, customer concentration and in-service PP&E.
If you hold anyway: keep it small, treat 199.54 and 195.10 as intentions rather than guarantees, and let deferred revenue, capex and financing terms decide whether you add.

Research Manager¶

Recommendation: Underweight

Rationale: The two sides ended up agreeing on almost every fact, risk and trigger. What separates them is whether to own NBIS before the Q3 print and the next financing. On the evidence, the bear wins that question, but not by enough for a Sell.

The bull's best points held up. Revenue grew about 454% year over year to $582M, and the dollar amount added each quarter is still rising. Deferred revenue is about $6.0B. The capex-lag table is a reasonable model: each quarter's revenue gain has been about 7.4–8.6% of the prior quarter's capex. Revenue per diluted share rose 2.3x while the share count rose 11%. Excluding SBC, operating margin improved from about -23% to -13%. The financing window is better now than it was in July.

The bull then conceded most of what decides the near-term trade: - The 'operations fund the build' claim was wrong. Underlying operating cash flow was about $0.2B against $5.66B of capex. - Valuation is rich. Using the debaters' own arithmetic (no sourced valuation data), the stock trades at about 28x trailing and about 20x forward run-rate sales. - Interest coverage is thin, at about 1.0–1.3x. - Dilution recurs at about 23% annualized. - The prepayment signal is ambiguous. Customer concentration, refund rights and seniority are unknown. - The 1.6x asset cover is a book number. - Liquidity covers about 1.7 quarters at the Q2 burn rate, so a raise before Q4 is likely. - Stops and the 'punitive financing' exit fire after the price has already moved. - The bull described the edge as 'a judgment on the slope, not a measured skew.'

Three bear arguments carried the call: 1. The asymmetry. A clean ~$808M Q3 only takes run-rate sales from about 21x to about 20x. Only the ~$1B path re-rates the stock, and the bull doesn't underwrite it. A stall breaks the model. 2. The timing. If Q2's capex mostly shows up in Q4, Q3 can't confirm the revenue slope. It can still disappoint on costs: deferred-revenue adds, margin after depreciation, capex and financing. 3. The nearest catalyst is probably a dilutive raise, and position sizing and stops don't protect against it.

The technicals are neutral to slightly cautious. Closing highs keep stepping down (286.69, 277.68, 243.88, 243.48), ADX is 18.6, ATR is 6.9% of price, and the stock fell 1.5% on a positive macro day. Insider data shows no open-market buys, even at $148.

I'm not going to Sell because the business is clearly real and growing fast. The longer-term trend is still up (above the 200-day SMA, weekly SuperTrend up). Both sides agree on specific triggers that would turn this constructive, and a clean print could gap the stock up 20–30%. The right stance is cautious, reduced exposure with a defined route back in.

Data gaps: no valuation or consensus data, no options pricing, no Q3 report date, no contract or customer-concentration disclosure, no split between in-service PP&E and construction in progress, and no NBIS-specific news or sentiment this week.

Strategic Actions: 1. Existing holders: trim to about 25–35% of a standard allocation before the Q3 print and the expected financing. Do it on strength into the 236–244 zone (near the 243.88/243.48 resistance) rather than chasing weakness. Size whatever remains so that another ~48% drawdown, like last summer's, is survivable. 2. No position: don't open a full position. At most, take a token 10–15% of standard allocation. If you want asymmetric exposure to the ~$1B-quarter path, a defined-loss options structure is better than shares, but options pricing isn't in our data, so check that it's economical first. 3. Downside exits for the remaining position: exit on a daily close below 199.54 (September low), and below 195.10 (daily SuperTrend) at the latest. Gaps are common, with ATR at about $16 and a precedent of +34% in a day and -19% over three sessions, so treat these as intentions, not guarantees. Also exit on any of these fundamental signals: a decline in the deferred-revenue balance, delivery slippage, a large discounted equity raise, a new expensive debt raise that pushes interest well above about $119M a quarter, or operating margin worse than -30% as depreciation rises. 4. Rebuilding exposure: (a) Go to about 50% of standard after a Q3 print with revenue at or above $800M, operating margin better than -30%, and a net deferred-revenue increase of about $1.2B or more. (b) Go to a full standard allocation (an upgrade to Overweight) once financing is done on non-punitive terms and the stock closes above 243.88 on volume with ADX above 25. © Add in tranches, not all at once. 5. What to watch: the Q3 numbers (revenue vs. ~$765M stall and ~$808M base; deferred-revenue adds; D&A step-up; interest; capex), whether the next raise is equity or debt and at what terms, and any disclosure of customer concentration, refund or penalty terms, or the in-service share of PP&E. 6. Re-evaluate the rating right after the Q3 print or any financing announcement, whichever comes first.

III. Trading Team Plan¶

Trader¶

Action: Sell

Reasoning: The research plan is Underweight, which maps to Sell. The case rests on asymmetry into the Q3 print and the likely dilutive financing. Operating cash flow of about $0.2B is set against $5.66B of capex, valuation is about 20x forward run-rate sales, interest coverage is about 1.0-1.3x, and liquidity covers about 1.7 quarters. The technicals do not argue against trimming: closing highs are stepping down (286.69, 277.68, 243.88, 243.48), ADX is 18.64, and price sits at its 10 EMA (232.22) with ATR near 6.9% of price. The long-term trend is still up (above the 200 SMA, weekly SuperTrend up), so this is a trim, not a full exit.

Entry Price: 240.0

Stop Loss: 199.54

Position Sizing: Existing holders: trim to about 25-35% of a standard allocation, selling into strength in the 236-244 zone. No position: do not open one, or at most a token 10-15% of standard allocation. Portfolio holdings were not provided, so apply these percentages to your own standard allocation.

FINAL TRANSACTION PROPOSAL: SELL

IV. Risk Management Team Decision¶

Aggressive Analyst¶

Aggressive Analyst: Neither of you has spoken yet, so I'll answer the arguments I expect, starting with my case for the Sell.

The most important number is the one that's easy to misread. Operating cash flow in Q2 was $2.25B, not $0.2B. But about $2.03B of that came from working capital, mainly customer prepayments and a one-time receivables collection. Strip that out and underlying operating cash is roughly $0.2B, set against $5.66B of capex. That is the gap the market has to fund, and free cash flow was -$3.4B in a single quarter. Cash of $8.0B covers somewhere between 1.5 and 2.5 quarters at that burn, depending on how you measure. Interest expense went from $4.8M to $119M in a year, and normalized EBITDA of $154M covers it only about 1.3x. The company has alternated debt and equity raises, and the next one is coming. The stock is priced for perfection into that raise, at roughly 20x forward run-rate sales by my back-of-envelope math, since the tools gave me no valuation data.

Now the expected pushback. The neutral analyst will say the long-term trend is intact: weekly SuperTrend up, price above the 200 SMA, RSI at 52.8, nothing stretched. All true, and that's why the plan is a trim rather than an exit. But ADX at 18.6 says the trend isn't doing any work right now. Closing highs are stepping down: 286.69, 277.68, 243.88, 243.48. We're at the 10 EMA with 6.9% daily ATR, so you're holding a full position through a binary event with no trend strength behind you. A bullish long-term structure doesn't protect you from a financing announcement. The August spike showed how fast this stock moves on news, and it gave back most of that move within a week.

The conservative analyst will probably say get out entirely. I disagree, because that's the version that leaves money on the table. Revenue is up 454% year over year, deferred revenue is about $6B, and operating margin improved from -110% to -30% in two quarters. A strong Q3 print can gap this stock 15-30% in a day, as August showed. Keeping 25-35% of a standard allocation preserves that upside, and the stop at 199.54 caps the downside on what's left. Selling into the 236-244 zone is also the aggressive move. It's the resistance band from the last two rallies, so you're selling where supply has already appeared twice. And you free up dry powder to rebuy after the financing, when dilution has been priced in and the stock may trade lower. Sitting at full size and hoping is the passive choice.

Some counterpoints deserve a straight answer. Insider selling is heavy and there are no open-market buys, but the trades cluster on the 1^st and 15^th, which looks scheduled, so I'd weight it lightly. The drop in share count from 322M to 271.9M is treasury cancellation, not a buyback, so it isn't real shrinkage, and Q2 still had a $2.85B equity raise. Macro is mixed: chips rallied and yields fell on 10/1, but Fed officials are still hawkish, and I have no actual rate, CPI or VIX values. The sentiment and company news feeds returned nothing, so I'm not leaning on them either way. The case rests on the cash flow and financing math, and on price structure.

If Q3 delivers a very large revenue beat with funded capex and no new raise, I'm wrong on the near term, and the residual position and a rebuy plan cover that. If it comes with a big financing, as the math suggests, you've sold near 240 and can buy back lower. That asymmetry is why I support the trim.

Apply the percentages to your own standard allocation, since I don't know your holdings: existing holders trim to 25-35%, sell into strength around 236-244, and keep the stop at 199.54. If you have no position, don't open one, or at most 10-15%.

FINAL TRANSACTION PROPOSAL: SELL Aggressive Analyst: We agree on direction, so the fight is over timing and size. First I'll concede what the other two got right, because some of it matters.

The neutral analyst is right about the SuperTrend math. The weekly stop is about 25% below the market, not 34%, and the monthly stop is about 51% below, not 104%. I also shouldn't have said operating margin improved from -110% to -30% in two quarters. It went from -110% to -32% in one quarter, then stalled at -30%. The conservative analyst is right that I don't know what drove the August gap, so "as August showed" was too strong. The data shows the stock can move 30% on something. It doesn't show what. A single limit order at 240 was thin, so I'll take the ladder at 236, 240 and 244. And I'm dropping the promise to buy it back lower. The Q2 raise came while the stock ran from about 102 to 287, so raises don't reliably mark bottoms. Re-entry should depend on conditions: financing terms known, capex funded for a few quarters, and trend confirmation.

Where I won't move is selling a chunk at market right now. The stock is 3.3% from 240, under half a day's ATR, so waiting costs little. The quarter ended yesterday, and companies typically avoid raising capital in the quiet window before they report. I can't confirm that for Nebius, but it suggests the gap risk before the print is lower than the conservative analyst fears. ADX at 18.6 and a 200 to 245 range say to sell at the top of the range, not the middle. August also supports selling into strength. The spike faded 19% in a week, from 277.68 to 223.90, so spikes are for selling into. I'll accept a deadline: if the ladder hasn't filled by the time an earnings date is announced, the rest goes before the print.

On the residual, the 1.4% math is a good method, but it gives a portfolio number, not a percentage of a standard allocation. It doesn't show that 15 to 25 beats 25 to 35. Between July 29 and August 14, 12 trading days, this stock went from 148.22 to 277.68, up 87%. A residual that small barely registers if the print is great and the raise comes into strength, which is the case the neutral analyst says I can't have both ways. But that's exactly why I keep a real core. It's the hedge for my own re-entry being wrong. Use a stop for the grind and sizing for the gap. The stop at 199.54 covers a slow bleed, and the size covers the gap. Pick your point in the 15 to 35 band from your own risk budget. I'd sit around 25 to 30.

I also don't like the neutral analyst's 50 SMA trigger. The stock closed at 207.37 on 9/15, below where the 50 SMA is today, and was back at 243.48 nine days later. Cutting on a close below 218.41 would have sold the low of that range. I'd keep the residual intact until the 199.54 break.

On fundamentals, the neutral analyst says the balance sheet isn't distressed, and I agree. My thesis was never solvency. It's the price of the next financing. But the burn range of -$3.4B to -$5.4B is more worrying than it looks, because the prepayment tailwind is shrinking. Deferred revenue rose about $3.2B in Q1 and only about $1.2B in Q2. Cash plus the $1.6B of securities covers roughly two to three quarters on reported burn and under two at the stripped burn. That's before accounting for the June 30 staleness and capex that doubled in one quarter. Interest runs about $475M annualized against roughly $616M of annualized EBITDA, and that's before any new debt. Diluted shares are already up about 11% in six months. My 20x is my own arithmetic, not a vendor figure: about 272M shares at 232 is roughly $63B, over a run-rate near $3.2B if Q3 lands around $800M. The share count may understate the fully diluted figure. On trailing Q2 it's in the high 20s.

Insiders I'll keep light. The mid-month pattern doesn't explain Korolenko's $101.6M on 5/13, so it isn't fully refuted, but there's no 10b5-1 confirmation either way. It's a small negative, not a trigger. I also agree the 1.5% drop on 10/1 is noise, and I never leaned on it.

For someone with no position, the 10 to 15% starter is optional, and I won't defend it hard. If you want exposure, the neutral analyst's entries are better: a pullback into 205 to 218 once financing is clearer, or a confirmed close above 243.88 with ADX through 25.

So the plan is a ladder at 236, 240 and 244, a deadline tied to the earnings date, a residual around a quarter of standard size, a closing stop at 199.54, and conditional re-entry. If the print is strong and funded, I still own a core and sold some at 236 to 244. If it comes with a big raise, I'm mostly out beforehand. Either way I'm not trading the middle of the range.

FINAL TRANSACTION PROPOSAL: SELL Aggressive Analyst: I'll start with the concessions, since the neutral analyst earned most of them.

The neutral analyst is right that the 20x figure is my own arithmetic and shouldn't be a headline fact in the trader's note. About 272M shares at 232 is roughly $63B, over a $3.2B run-rate that itself assumes Q3 lands near $800M. For a company growing 46% a quarter, that isn't obviously perfection, and it says nothing about timing. I'd move it to a footnote. The runway should also be a range, not 1.7 quarters. On $9.6B of cash and securities, it's under two quarters at the stripped burn of about $5.4B, nearly three at the reported $3.4B, and six-plus on the trailing average, all before whatever happened in Q3. I'll use liquidity for direction, not for timing.

I also take the neutral analyst's point about the quiet window. I used it to say gap risk before the print is lower. The same logic says a raise would likely arrive with the print, at the open, where no stop or ladder helps. So the size carried into the event matters most. That's why I offered an earnings-date deadline, and I'll make it firmer: whatever hasn't sold by the time a date is announced goes before the print.

I'll also take the 218.41 trigger as the neutral analyst rewrote it. A close below it means finishing the ladder at market, which gets you to the target without going under it. That avoids the 9/15 problem, where cutting at 218 would have sold the low. I would not add a separate cut at 205. The September low close was 199.54 and 205 is only about 2.7% above it, so that rule and my stop are nearly the same decision.

On timing, the neutral analyst's probability framing beats the conservative analyst's payoff-only comparison. Waiting costs about 3% on the shares sold if the stock bounces. Not waiting costs much more only if a 20% gap arrives before the bounce. With 7% daily ranges, touching 240 looks much likelier than that sequence. Still, a third of the reduction done now is cheap insurance against a news gap we can't see, and I won't fight it. So I'll move: sell roughly a quarter to a third of the reduction this week, ladder the rest at 236, 240 and 244, and stop selling if we get a close above 243.88 with ADX through 25.

Now the real remaining disagreement, which is the residual. The conservative analyst says we can't know which direction the next big move goes, so size for survival. I agree with that, but "we're blind" doesn't set a number, as the neutral analyst said. A loss budget does. The cost of going too small is real. The stock went from 148 to 278 in twelve trading days, and Q2 revenue grew 454% year over year with $6B of deferred revenue behind it. If the print is strong and funded, a 10% position captures almost nothing, and a 25% position captures a meaningful amount. Going from 20 to 25% is a small difference in downside, and you only choose it if your loss budget on a 35% gap allows. So I'll settle at 25%, inside the neutral analyst's range and at the conservative analyst's stated ceiling. If your budget says 20, take 20. The stop at 199.54 handles the slow grind, and the size handles the gap.

The conservative analyst is right that a closing stop executes at the next open and carries gap risk itself. It's a grind control, not a gap control. I'd skip the options hedge. On a name moving 7% a day, protection will be expensive, and the cheaper hedge is owning fewer shares.

Nothing in the fundamentals has changed my view on direction. The burn is real, and the prepayment tailwind is fading: deferred revenue rose about $3.2B in Q1 and about $1.2B in Q2. Interest is about $475M annualized against roughly $617M of annualized normalized EBITDA, with no new debt included. Diluted shares are up about 11% in six months. But the balance sheet isn't distressed. The risk is the price of the next financing, not solvency, and that is a reason to trim into strength, not to exit. Insider selling stays a small negative, with no confirmed 10b5-1 plans and no open-market buying, but I wouldn't trade on it.

Before anything else, someone should check the earnings date and whether a raise already happened in Q3. Those are the cheapest facts we're missing, and they could change the schedule.

The plan: sell about a quarter to a third of the reduction now, ladder 236, 240 and 244, finish before the print once a date is announced, and finish at market on a close below 218.41. Hold a residual near 25% of a standard allocation, sized to a loss budget, with the closing stop at 199.54. Open no new position, or wait for a pullback into 205 to 218 or a confirmed breakout. Rebuy only when financing terms are known, capex is funded for several quarters, and the trend confirms. If the print is strong and funded, you still own a core and sold some at 236 to 244. If a big raise comes, you're mostly out beforehand.

FINAL TRANSACTION PROPOSAL: SELL (a staged trim to about 25% of a standard allocation, not a full exit) Aggressive Analyst: Most of this has converged, so I'll concede what I should and then fight for the parts that still matter.

The conservative analyst caught a real contradiction in my plan. I can't say "stop selling on a close above 243.88 with ADX through 25" and also "finish before the print." The chart can set the pace, but the pre-print number is fixed. A breakout means I use the full window up to the backstop date instead of pushing anything at market. It doesn't mean I carry extra size into the open of the print. I also accept a calendar backstop, something like the third week of October, whether or not an earnings date has been announced. That's the neutral analyst's judgment call rather than data, but it costs almost nothing.

On the 205 half-cut, I was wrong to wave it off. If 205 and 199.54 are nearly the same decision, taking the first one just turns one closing-stop trigger into two, and a closing stop fills at the next open anyway. So the residual halves below 205 and exits below 199.54. I won't also lower the cap to pay for it. A 25% ceiling, a half-cut and a full exit is already a graduated risk plan.

Sizing is where I want to be careful. The neutral analyst's arithmetic settles it. If you'd accept losing half a percent of the portfolio on a 35% gap, the residual is about 1.4% of the portfolio. That's roughly 29% of a 5% standard allocation and 18% of an 8% one. So the loss budget picks the number, and arguing 20 versus 25 is noise. I disagree with a hard 20% ceiling because it pre-judges what the formula should say. I'll cap myself at 25 so I'm not arguing against my own trim thesis, and anyone whose budget says 15 should take 15. What I won't accept is going toward 10%. Revenue is up 454% year over year with about $6B of deferred revenue behind it, and the stock went from 148 to 278 in twelve trading days. At 10% you pay for insurance and own almost no upside. The aggressive version of this trade isn't holding full size into a financing. It's holding a real core and keeping dry powder to act when the financing is known.

On timing, the conservative analyst's point that a raise tends to come into strength helps my side. If the company raises into strength, the strength has to arrive first, and that fills the ladder at 236 to 244. The scenario that hurts the ladder is a raise or a news gap from 232 with no bounce. The backstop and a third sold this week cover that. I agree the first third shouldn't wait. Checking the earnings date and whether anything was raised in Q3 takes minutes, and the answer should tune the pace of the rest, not whether the first third goes.

The conservative analyst is also right that the six-plus quarter runway from trailing average burn is the least relevant number, because capex is now $5.66B against $2.47B and deferred revenue growth slowed from about $3.2B to about $1.2B. The neutral analyst is equally right that I can't treat Q3 cash as both unreliable and certain to be diluted. The honest answer is a range, with the forward weight on the short end, and a check today. I never relied on net debt, so the $503.6M versus roughly $2.1B discrepancy doesn't touch my numbers, but I agree nobody should use it until it's reconciled.

I'll also take the neutral analyst's edits to the note. The 20x multiple goes in a footnote as our own arithmetic. Interest coverage is stated as about 1.3x on normalized EBITDA, with about $475M of annualized interest against about $617M of annualized EBITDA, and negative on operating income. The plan also says plainly that a rebuy conditioned on a close above 243.88 may be above where we sold. That's the price of insurance, and I'd rather say so than pretend it's free.

On proceeds, the neutral analyst is right. Rotating into other high-beta AI or chip names removes single-name event risk but keeps the same capex-cycle and rates exposure. If that's the intent, fine, but say it. I'd rather the proceeds sit as dry powder for a pullback into 205 to 218 or a financed, confirmed breakout.

So the plan is this. Check the earnings date and Q3 financing today. Sell about a third of the reduction this week. Ladder 236, 240 and 244. Finish before the print once a date is announced, or by the backstop date, whichever comes first. A close below 218.41 means finish the ladder at market. The residual is sized from your loss budget and capped at 25% of a standard allocation. Halve it on a close below 205 and exit on a close below 199.54. Open no new position. Rebuy only when financing terms are known, capex is funded for several quarters, and the trend confirms. If the print is strong and funded, you still own a core and sold some at 236 to 244. If a big raise lands, you're mostly out beforehand.

FINAL TRANSACTION PROPOSAL: SELL (a staged trim to a loss-budget-sized residual capped at about 25% of a standard allocation, not a full exit) Aggressive Analyst: I'll take the concessions first, because the sizing argument went against me and I'll say so. The conservative and neutral analysts are right that I can't say the loss budget picks the number and then say I won't go toward 10%. A formula with a floor isn't a formula. If someone's standard allocation is 10% of the portfolio and their budget is half a percent on a 35% gap, they land near 14% of standard, and that's the answer. The plan is a cap of 25%, no floor, and the budget decides. I'd add that if the budget keeps pushing you toward 10%, your standard allocation was too big for this stock before any of this started. That's a sizing problem, not a reason to dump the name.

I also agree the budget should be portfolio-wide. If the proceeds go into other high-beta AI or chip names, the NBIS trim removes single-name event risk but keeps the capex-cycle and rates exposure, and you've spent the budget twice. I'd park the proceeds in cash or bills as dry powder for a pullback into 205 to 218 or a financed, confirmed breakout. Tax lots are a fair catch too. Check which lots go first before the first order.

Where I still push is on the upside case, because the conservative analyst's base-effect point only goes so far. Yes, 454% year over year comes off a $105M quarter. But the Q3 comparison is a $146M quarter, and even my rough guess of $800M puts that at about 5.5x, still north of 440%. And 37% sequential growth, which is the slower number, compounds to roughly 3.5x annualized. The business is real. I'm not leaning on a headline that evaporates.

I also don't accept that I can't cite the prepayment fade to justify the sell and still hold a core. The neutral analyst is right. Trimming is about the cost of the next financing and a stock that has to hit a smooth path. Keeping a core is about contracted demand and a stock that has gapped up 30% on news none of us can see. Holding some of a name you're underweight in is what an underweight is.

The neutral analyst's point on the 35% figure helps me. It's a stress number, not a forecast. Financing-day reactions are more plausibly 5 to 15%, and on a 25% residual that costs a point or two of allocation. A 25% cap isn't reckless. It's the price of staying in a name where the upside tail is as real as the downside one.

On the backstop, I accept a hard calendar date and I accept that the chart can't move it. A breakout can pause the ladder but not extend the deadline. I'd take the neutral analyst's window, pick a date around the 20^th, tighten it to a few days before the print if one is announced, and write it down. A mid-October market sale weeks ahead of a print that probably isn't until November gives up a bounce for little protection. But that's the decimal-point fight we already named. Pick the date and don't renegotiate it.

So the plan is this. Check the earnings date and any Q3 financing today, but don't hold the first third for the answer. Sell about a third of the reduction this week. Ladder the rest at 236, 240 and 244. A close above 243.88 with ADX through 25 pauses the ladder but doesn't change the pre-print number. A close below 218.41 finishes the ladder at market. The calendar backstop is unconditional. The residual comes from a portfolio-wide loss budget, capped at 25% of a standard allocation with no floor. Halve it on a close below 205 and exit on a close below 199.54, knowing a closing stop can gap. Open no new position. Rebuy only when financing terms are known, capex is funded for several quarters, and the trend confirms, and say plainly that this may mean buying back above where you sold.

If the print is strong and funded, you still own a core and sold some at 236 to 244. If a big raise lands, you're mostly out beforehand. The aggressive version of this trade was never holding full size into a financing. It's holding a real core and having cash ready when the financing is known.

FINAL TRANSACTION PROPOSAL: SELL (a staged trim to a loss-budget-sized residual, capped at about 25% of a standard allocation with no floor, not a full exit)

Conservative Analyst¶

Conservative Analyst: I agree with the aggressive analyst on direction, so my disagreement is about how much risk is left in the plan. Reducing exposure is right. I think the trim is too slow, too dependent on a rally, and leaves too much behind.

Start with what I'd tighten. The plan assumes we get to sell into 236-244, but the stock is at 232.28 and that zone needs a 2 to 5 percent bounce first. If the financing or the print lands before the bounce, there's no fill. The August spike was a 34 percent gap in a single session, from 193.23 to 259.20, and gaps go down as well as up. A stop at 199.54 is a closing level 14 percent below the market. It is not a guarantee, because on a gap the stop fills wherever the stock opens. So I'd stage the trim: do a meaningful part of it now, and leave only the remainder for the 236-244 zone, with a deadline well before the print.

On the residual, 25 to 35 percent of a standard allocation in a name with 6.9 percent daily ATR is still a lot. I'd go to 15 to 25 percent. Size it so a 35 percent gap against you is a loss you've already agreed to. For example, if you'd tolerate half a percent of the portfolio on this idea, the residual shouldn't be much more than about 1.4 percent of the portfolio. For anyone with no position, I'd say zero. A token 10 to 15 percent starter buys nothing ahead of a binary event when we don't even know the earnings date.

The aggressive analyst's rebuy logic worries me most. The claim is that you sell near 240 and buy back lower after dilution is priced in. But the same analyst argues a strong print can gap the stock 15 to 30 percent. If that happens, the company can raise into strength, and you'd be chasing a rebuy higher. The rebuy should be tied to conditions, not a hoped-for price: financing terms known, funding visible for the next few quarters of capex, and a close above 243.88 with ADX moving through 25.

On the "upside left on the table" argument, the August spike faded within a week, from 277.68 on 8/14 to 223.90 on 8/19, about 19 percent. If upside gaps fade that fast, you don't need to hold size through the event to participate. You can look at the print and act. Also, nothing in our data says what drove the August move. The news feed returned nothing, so calling it a Q3-style earnings reaction is an assumption.

I'd push back on a few of the fundamental framings, even though the cash flow math is sourced and sound.

Interest coverage is worse than the 1.3x quoted. That is EBITDA over interest. Operating income is negative $176M, so on an operating basis there's no coverage. Interest also jumped from $63.7M to $119.1M with no new debt in Q2, which is the full-quarter effect of the Q1 raise. That's roughly $475M annualized before any new borrowing.

The "operating margin improved from -110% to -30% in two quarters" line hides the fact that it was -32% in Q1 and -30% in Q2. The improvement stalled. Sequential revenue growth also slowed from 75 percent to 46 percent. R&D almost tripled quarter on quarter, from $67.4M to $191.0M, and the operating loss widened in dollars. Net PP&E went from $8.4B to $14.9B, so depreciation, which reported gross margin mostly excludes, will climb as that capacity comes online.

The roughly $6B of deferred revenue is a delivery obligation as much as a demand signal. It funded about $1.2B of Q2 operating cash, and we don't know who the counterparties are or what happens if capacity slips.

Liquidity is staler than it looks. The $8.04B of cash is a June 30 number, and Q3 ended yesterday. Capex went from $2.47B to $5.66B in one quarter, so burn isn't steady. Adding the $1.6B of securities stretches the runway, but not by enough to remove the funding need. We also can't tell whether a raise already happened in Q3, because the news feed was down. That uncertainty argues for being smaller, not for staying put.

On insider selling, "scheduled on the 1^st and 15^th" doesn't cover the biggest trades. Korolenko's $101.6M sale was on 5/13. Director Ryan's $13.3M sale at $263 to $270 was on 8/14, right at the August closing high. Boroditsky's sale was on 9/14. The tool also doesn't confirm any 10b5-1 plans. There is no open-market buying either. I wouldn't call this a signal, but I wouldn't wave it away. Share count is another quiet cost: diluted shares went from 253M to 280.4M in six months, about 11 percent.

I also expect the neutral analyst to say the trend is intact, since the weekly SuperTrend is up and price is above the 200 SMA. That's true, but the weekly stop is at 172.93, 34 percent below the market, and the monthly stop is 104 percent below. Those are not risk controls. They're an admission that you'd sit through a one-third drawdown. And the stock has done something close to that inside the "intact" trend: from 286.69 on 6/18 to 148.22 on 7/29, down about 48 percent in six weeks.

The neutral analyst may also say the missing news, sentiment and macro data cancel out, so stay balanced. I read it the other way. We're blind on the earnings date, financing news and customer contracts, and unknown variance is a reason for smaller size. The one fresh read we do have is mildly negative. On 10/1, with headlines describing chips up and yields down, NBIS opened at 236.18 and closed at 232.28, down 1.5 percent on volume of only 12 to 15M shares. MACD is slipping off 4.78 and ADX fell from 20.25 to 18.64.

The aggressive analyst calls holding full size the passive choice, and I agree. The conservative choice here is to sell and to sell sooner than the plan implies. Trim now rather than waiting for a rally, hold a smaller residual with its loss defined in advance (ideally hedged with options if available, or at least backed by a hard stop), open no new positions, and rebuy only on stated conditions.

FINAL TRANSACTION PROPOSAL: SELL Conservative Analyst: Let me start with my own corrections. The neutral analyst is right about the SuperTrend math. The weekly stop at 172.93 is about 25 percent below 232.28, and the monthly stop at 113.82 is about 51 percent below. I measured from the stop up to the price instead of from the price down to the stop. The point survives, since a 25 percent drawdown to the weekly stop is not a usable risk control, but I should have gotten it right. I'll also drop the 10/1 session as evidence. A 1.5 percent dip on light volume is a quarter of an ATR, and I shouldn't have called it a signal. My case doesn't need it.

To the aggressive analyst: I'm glad the rebuy-lower story is gone and the ladder is in, because that narrows the fight to timing and size. On timing, you say waiting costs little because 240 is 3.3 percent away. Run that cost. Selling at 232 instead of 240 gives up about 3 percent on the shares you sell. If the sold chunk is a quarter of a standard allocation, that's under one percent of an allocation. Being unsold when a 30 percent gap arrives costs roughly ten times that. The quiet-period argument is also something you admitted you can't confirm, and financing is only one source of gap risk. Our own data shows two huge moves with no explanation in any feed: 193 to 259 in a single session in August, and 286 to 148 in six weeks into late July. A customer announcement, a capacity delay, an Nvidia comment or a hawkish Fed day can do the same. A plan that waits for a bounce assumes the stock gives you one before the news arrives.

I like "stop for the grind, size for the gap," but it argues for a smaller residual than you want. A closing stop at 199.54 is evaluated after the bell and executes at the next open, so it carries gap exposure itself. You're right that a small residual barely participates in an 87 percent run like the one from July 29 to August 14. That is the price of insurance, and the same stock also fell 48 percent in six weeks. We can't tell which direction the next big move goes, and that is the reason to size for survival.

The liquidity point also cuts against you more than you allow. The $8.04B of cash is from June 30, so a full quarter of burn has presumably already gone out. If no raise has closed, a burn near the reported $3.4B would leave something closer to $4.6B plus $1.6B of securities. I can't verify that, and the neutral analyst is right that any runway figure is imprecise. But the staleness points toward caution.

On the neutral analyst's 50 SMA trigger, you have a fair point about whipsaw, though the 50 SMA on 9/15 isn't in our data, so we can't prove it would have fired then. I'd treat that level as a prompt to reassess, not an automatic cut.

To the neutral analyst: your plan is close to the one I'd build, so I'll be brief. You call 232 the middle of the range, but in a 200 to 245 range it's roughly 70 percent of the way up. It's not a terrible place to start selling. You say a gap happens at the open and you can't act before it. I agree, and that makes the size going into the event the only real control. It's why I'd treat 25 percent as a ceiling and aim nearer 20, or whatever a pre-agreed loss on a 35 percent gap implies. I accept that ten points of allocation isn't where this is won, and the loss budget should decide, not a round number. I also agree the balance sheet isn't insolvent. But the cost of the next financing is set by the stock and credit markets on the day it prices. With about $475M of annualized interest against roughly $617M of annualized normalized EBITDA, and a quarter that burned $3.4B after $5.7B of capex, that cost matters. The net debt discrepancy, $503.6M reported against about $2.1B computed, is also still unresolved. And I fully agree on compression. Lower highs and higher lows with 7 percent ATR will resolve violently in one direction, and nobody here can say which.

So my plan is this. Sell about a third of the intended reduction now or this week, ladder the rest at 236, 240 and 244, and put a hard deadline on it. The ladder either fills or the remainder is sold when an earnings date is announced, whichever comes first. Hold a residual around 20 percent of a standard allocation, sized to a loss you've already accepted, with the closing stop at 199.54 and an options hedge if you have access. Don't start a new position. Rebuy only when financing terms are known, funding for the next few quarters of capex is visible, and the trend confirms with a close above 243.88 and ADX through 25.

FINAL TRANSACTION PROPOSAL: SELL Conservative Analyst: Let me start with what we now agree on, because that narrows the fight. Everyone wants to sell about a third of the reduction now, ladder the rest at 236, 240 and 244, tie a deadline to the earnings date, drop the rebuy-lower story, and rebuy only on conditions. The disagreement is about size and about three details where I think your plans contradict themselves.

First, to the aggressive analyst. You say you'll settle at 25%, with 20% if the loss budget says so. But you also say the cheaper hedge is owning fewer shares because options on a 7%-a-day stock are expensive. That argument points to the smaller number. A gap against you is the one loss a stop can't cap, since your own closing stop executes at the next open. The July to August run from 148 to 278 is the upside case for holding more, but the fall from 286 to 148 in six weeks is the same stock behaving the opposite way. A 10% position missing most of a great print is the price of insurance. And since you've conceded the raise probably lands with the print, I'd set 20% as the ceiling and let the loss budget push it lower.

Your rule to stop selling on a close above 243.88 with ADX through 25 also conflicts with your own firmer deadline. If that breakout happens in two weeks and then the date is announced, you're carrying more than your target into a binary event. A breakout should change the pace of selling, not the amount you hold at the open of the print. The neutral analyst said exactly that, then also said to stop pushing sales into a breakout, which has the same tension. I'd write it down plainly: the chart can pause the ladder, but the pre-print number is reached regardless.

On the 205 cut, I think you're wrong to reject it. If 205 and 199.54 are nearly the same decision, taking the first one costs almost nothing. It also turns an all-or-nothing closing stop into two steps. A single trigger that fires after the bell and fills at the next open, in a stock with a 16-point ATR, is a weak control. Halving the residual on a close below 205 and exiting the rest below 199.54 is cheap and graduated.

To the neutral analyst. Your probability framing is fair, and I'll concede it for the part of the sale we're waiting on. Break-even is around 13 to 15%, and a touch of 240 is probably more likely than a gap first. But I'd add that if the company raises capital, it tends to do so into strength. The one financing cycle we can see, the Q2 equity raise, happened during a run to 287. So the bounce to 240 is also the stretch when a raise is most likely, which makes me less relaxed about waiting on the rest than you are. That's inference, not data, but it argues for the earnings-date deadline plus a time limit that doesn't depend on a date being announced.

I'd also push back on the runway range. The six-plus quarters comes from the trailing average of about $1.5B a quarter, but that average includes quarters when capex was $2B to $2.5B and deferred revenue was growing by $3.2B. Capex is now $5.7B, and deferred revenue growth slowed to about $1.2B. The trailing average is the least relevant number we have. And if the Q3 cash is far above $8B, it's because a raise already happened, which is the dilution this trade is meant to protect against. It can't be a reassuring runway number and an irrelevant dilution number at once.

Your point that "we're blind, so go smaller" has no stopping point is right. That's why I'd use the loss budget. Size the residual so a 35% gap is a loss you've already accepted, which is the budget divided by 0.35. If that lands at 20% of a standard allocation, take 20, and if it lands lower, take lower.

Two loose ends. The net debt discrepancy between $503.6M reported and about $2.1B computed is still unresolved, and nobody should lean on net debt until it's reconciled. And checking the earnings date and Q3 financing is the cheapest information we're missing, so do it today. I wouldn't hold the first third of the sale until you have the answer.

My plan: sell about a third of the reduction now, ladder 236, 240 and 244, and finish before the print once a date is announced or within a fixed number of weeks, whichever comes first. Cut the residual again on a close below 205, with the final exit on a close below 199.54. Cap the residual at about 20%, or lower if the loss budget says so, and open no new position. Rebuy only when financing terms are known, capex is funded for several quarters, and a close above 243.88 comes with ADX through 25.

FINAL TRANSACTION PROPOSAL: SELL Conservative Analyst: I think we're now arguing about where to put the decimal point, so let me say where I agree and where I still push.

I'll concede the neutral analyst's sizing arithmetic. Twenty versus twenty-five percent moves the outcome by under two points of allocation either way, and I shouldn't defend a round number as if it were analysis. But that cuts against the aggressive analyst's last move. You said the loss budget picks the number, and then you said you won't go toward 10%. Those can't both stand. The same formula gives about 29% of standard for someone whose standard allocation is 5% of the portfolio, and about 14% for someone at 10%. For a large standard allocation, the budget lands near the low end of your range, and a floor that overrides it contradicts your own rule. The cap of 25 is fine. The plan should say there's no floor and that the budget can take you lower.

On the upside case, you lean on 454% year-over-year growth, but that's a base effect from a $105M quarter. The more relevant numbers are sequential growth slowing from 75% to 46%, and your own $800M Q3 guess, which would be about 37%. You also pointed out that deferred revenue growth fell from about $3.2B to about $1.2B. That means the next strong print has to be funded some other way, and that's the dilution risk we're trimming for. You can't use the prepayment fade to justify the sell and then use the same fundamentals to justify holding a bigger core.

On raising into strength, you're right that a gap up fills the ladder at a better price, so I'll drop that objection. The scenario I care about is the other one: an after-hours convert or equity offering, priced at a discount, and a stock that opens down from 232 with no bounce. A third sold this week covers a third of the reduction. That's why the backstop has to be unconditional, which means sell the remainder at market on that date whatever the chart says. I'd put it in the first half of the window you named, mid-October rather than the third week. You've already accepted that the chart can pace the ladder but can't change the pre-print number, so the date shouldn't be negotiable either.

To the neutral analyst, I accept the point that you'd lean to the upper end of the range if a Q3 raise already closed. I'd let that check move the pace, not the cap. A raise like Q2's, $2.85B, covered less than one quarter of that quarter's $3.4B free cash flow burn, and capex is still rising. A closed raise buys time but doesn't remove the next financing. I also accept that the debt raise came with the stock near 100, so my raise-into-strength point rests on one data point and I shouldn't lean on it.

Your proceeds point is the most useful new thing in the discussion, and I'd go further. The loss budget should be portfolio-wide, not per name. If the proceeds go into other high-beta AI or chip names, a bad day for the capex cycle or a hawkish Fed hits them together, and the budget you set on a 35% gap in NBIS is already spent elsewhere. Count all correlated holdings in the budget, and until the financing is clear I'd park proceeds in cash or bills.

Finally, on process, we now have a ladder, a first-third sale, a backstop date, an earnings trigger, a 218.41 trigger, a 205 half-cut, a 199.54 exit, a cap, and rebuy conditions. Write the dates and levels down before the first order goes in. The risk with a plan this detailed is renegotiating it mid-week, on a day when the stock is up 4% and everyone feels clever. I'd also check the earnings date and any Q3 financing today and not hold the first third for the answer. A cheap check shouldn't delay the cheapest insurance in the plan.

My version is therefore the shared plan with three edits: no floor on the residual, an unconditional mid-October backstop, and the loss budget measured across correlated holdings.

FINAL TRANSACTION PROPOSAL: SELL Conservative Analyst: Most of the plan is settled, so I'll just say where I've landed and then push on what's left.

Settled: sell about a third of the reduction this week without waiting on the date check, ladder the rest at 236, 240 and 244, and finish at market on a close below 218.41. Halve the residual below 205 and exit below 199.54. The chart can pause the ladder but can't change the pre-print number. The residual comes from a portfolio-wide loss budget, capped at 25 percent of standard with no floor. I'm dropping 20 as a number of my own. If the formula says 20, or 14, that's the answer. I'd ask that the trader's note say "up to 25, and probably lower for a large standard allocation," so nobody treats 25 as the default.

Aggressive, you said a 5 to 15 percent financing-day drop on a 25 percent residual costs a point or two of allocation. The arithmetic is about 1.25 to 3.75 points, so the top of your own range is nearly four. With ATR at 6.9 percent, a 15 percent move is only about two ATRs, which is an ordinary bad stretch for this stock, not a tail. The 5 to 15 range is also a judgment made in this conversation. Nothing in our data shows how the stock reacted to any financing, and we don't even have the date of the Q2 equity raise. I accept 35 percent as a stress number, but the point of stress sizing is that you don't get to pick the tail you're comfortable with afterward.

On the upside case, the 440 percent year-over-year figure can't tell us whether Q3 is good. With a $146M base it will be north of 400 percent on almost any plausible print, so a number that looks the same for a great quarter and a mediocre one is a weak reason to hold more. The $800M is our own guess, and the 3.5x annualized figure assumes 37 percent growth for four straight quarters after a sequence of 75 and 46. Most importantly, that growth is gated by capex, and capex is gated by financing. The growth you want to own is the growth that needs the raise we're trimming for. I have no objection to a core position, but I don't think the growth story justifies a bigger one.

On the backstop, I'll move. The 20^th versus mid-October is the decimal-point fight we already named. But "the print probably isn't until November" is an inference, and we have no date. The print also isn't the only event. A convertible or equity offering can price on any evening, and companies often raise right after they report, when disclosure is fresh. That's inference too, but it means there may be no clean quiet window. So pick a date no later than the 20^th, write it down, tighten it if an earnings date is announced, and make it unconditional. If the stock bounces to 244 on the 17^th, the remainder still goes by the 20^th.

Neutral, I accept the tax point and the proceeds point. Tax is a known, finite cost and a gap isn't, so tax should decide which lots go first, not when. On proceeds, cash or bills until the financing picture clears.

I'd resist one thing. You say my lean toward the low end rests on an unobserved gap down. True, but the data covers six months, and in that window the stock fell 48 percent in six weeks, with 39.8M shares on the low day. Our only observed one-day gap was up 34 percent. With that range of outcomes and a company that burned $3.4B in one quarter, calling the downside tail unobserved doesn't make it smaller.

Three things should go in the trader's note as open items. The $8.04B of cash is a June 30 figure, so Q3 liquidity is unknown. The net debt discrepancy of $503.6M reported against about $2.1B computed is unresolved, so nobody should lean on net debt. And a rebuy gated on a close above 243.88 may be above where we sold, which is the cost of the insurance and should be stated plainly. Write the dates and levels down before the first order goes in, so a +4% day doesn't tempt anyone to renegotiate them.

FINAL TRANSACTION PROPOSAL: SELL (a staged trim to a loss-budget-sized residual, capped at about 25% of a standard allocation with no floor, with an unconditional backstop date no later than the 20^th, not a full exit)

Neutral Analyst¶

Neutral Analyst: You two agree on the direction, so let me go after the execution, since each of you leans on evidence that can't carry the weight you put on it.

Aggressive first. Your plan is basically one limit order at 240, and that's not a plan. The stock is at 232.28, and 240 is about 3.3% away, which is under half of a normal day's range at a 6.9% ATR. A fill is quite likely over the next few days, but "likely" isn't "certain", and a single price leaves you with nothing if the stock rolls over from here. A ladder across 236, 240 and 244 handles that better.

Your cash flow framing is also too tidy. Calling about $0.2B the underlying operating cash flow treats customer prepayments as if they weren't real money. In a business where customers prepay for capacity, deferred revenue is how the build gets funded, and it's also a delivery obligation. The honest burn sits somewhere between the reported -$3.4B and the roughly -$5.4B you get when you strip out working capital. The runway figure also rests on a June 30 cash balance, three months stale, with no news feed to tell us whether anything was raised since. A 1.7-quarter runway has false precision.

I don't buy the rebuy-lower-after-the-raise story either. In the one financing cycle we can see, the quarter with the $2.85B equity raise was the quarter the stock went from about 102 to a closing high of 287. Raises don't reliably mark bottoms or tops, and a financing can also remove an overhang. And you can't argue that a strong print gaps the stock 15 to 30% and also expect a calm, cheap re-entry.

Now the conservative analyst. You made a numerical slip that matters. The weekly SuperTrend stop at 172.93 is about 25% below the market, not 34%. The 34% is how far the close sits above the stop. The monthly stop at 113.82 is about 51% below price, not 104%. Your underlying point survives, since those stops aren't practical risk controls. But a one-quarter drawdown to the weekly stop is less dramatic than the one-third you described.

I also think you over-read the latest session. A 1.5% decline on 12 million shares, in a stock that moves 6.9% on a typical day, is a quarter of one ATR. That's noise, not a mildly negative signal. MACD's histogram is still positive, OBV was higher on the second test of 243 than the first, and the pullback came on light volume. None of that is bullish enough to hold full size, but it doesn't say sell hard right now.

Selling a meaningful chunk immediately is also selling the middle of a 200 to 245 range. You're 14% above 199.54, about 5% below resistance, and sitting on the 10 EMA. That's the least favorable spot for a seller. And the urgency assumes the print is imminent, but the quarter ended yesterday. I can't confirm the date, but a company doesn't report the day after quarter end, so we likely have weeks, not days.

"Look at the print and act" doesn't work either. A gap happens at the open, and you can't act before it. Your own August example fell 19% in a week, but the stock still ended September above the pre-gap level of 193. Fading gaps aren't a reason to sit out entirely.

You're right about the interest burden. But the balance sheet isn't distressed: $8B of cash, $0.8B restricted, $1.6B in securities, against $10.2B of debt. The risk is the price of the next financing, not solvency. And the gap between your residual (15 to 25%) and the aggressive one (25 to 35%) is ten points of a standard allocation. That is not where this decision gets won or lost. The process is.

On insiders, you're both partly right. Ryan on 8/14, Boroditsky on 9/14 and Boynton's monthly sales all land within a day or two of the 15^th, so the pattern isn't refuted, but the tool doesn't confirm any 10b5-1 plans and there's no open-market buying. Treat it as a small negative, and don't treat the mid-October filings as news.

What neither of you addressed is the structure. Closing highs are stepping down (287, 278, 244, 243) while closing lows are stepping up (148, 200, 207). That's compression, and with ATR near 7% it will resolve. The position should be sized so that either resolution is survivable.

So here's the moderate version. Existing holders should aim for a residual around 25% of a standard allocation, staged in three steps. Do roughly a third of the reduction now or this week, so you aren't dependent on a bounce. Place another third as limit orders at 236, 240 and 244. Make the rest conditional. A daily close below the 50 SMA at 218.41 takes the residual down to 15 to 20%. A close above 243.88 with ADX rising through 25 and real volume means you stop selling, keep the core, and don't add until financing is clear.

The final stop on the residual is a closing break of 199.54, just above the daily SuperTrend at 195.10. Because the residual is small by design, gap slippage there is a loss you've already accepted. Rebuy on conditions rather than price: financing terms known, funding visible for the next few quarters of capex, and trend confirmation.

If you have no position, I'd side with the conservative analyst for now and not start a token position. A better entry is either a pullback into the 205 to 218 area once the financing picture is clearer, or a confirmed breakout. A 10 to 15% starter just adds exposure to an event we can't time.

This works across the scenarios. A strong print gapping up leaves you with a core position and some shares already sold at 236 to 244. A dilutive raise leaves you mostly out beforehand. Continued chop means you sold near resistance without having dumped at the midpoint.

FINAL TRANSACTION PROPOSAL: SELL (a staged trim to roughly a quarter of a standard allocation, not a full exit) Neutral Analyst: We've converged more than this format usually allows, so I'll skip the recap and go at what's still unresolved.

First, two concessions. The conservative analyst is right that 232 isn't the middle of the range. On closes between 199.54 and 243.88 it sits about three-quarters of the way up, so I overstated that. The aggressive analyst is right to push back on my 50 SMA trigger. The stock closed at 207.37 on 9/15 and was at 243 nine days later, and a hard cut at 218 risks selling a low. The conservative point holds too, that we can't prove where the 50 SMA was on 9/15. Still, I'll change the trigger. A close below 218.41 means finish the ladder at market, which gets you to the target without going below it. Only a close under about 205, the lower Bollinger band and the bottom of the September range, justifies cutting the residual further.

Aggressive, I won't follow you to 25 to 30 percent, and your reason is the problem. You said the core is the hedge against your own re-entry being wrong. That's a reason to hold size through a binary event, and those are the moments a stop can't help. Your quiet-window argument also cuts the other way from how you used it. If companies tend to avoid raising capital between quarter-end and the print, then the raise and the earnings likely land together, at the open, when nobody can sell. That makes the size you carry into the print the number that matters. It's a case for a hard cap, not for relaxing.

I'd also flag two things in the rationale. The 20x sales multiple is your own arithmetic, with no vendor data, no peers and no consensus behind it. For a company growing revenue 46 percent a quarter, 20x run-rate isn't obviously perfection. It supports the direction but says nothing about timing, so it shouldn't sit in the trader's note as a headline fact. The runway claim is also softer than it looks. Free cash flow was about -$0.2B in Q1, about -$1.5B per quarter on the trailing average, -$3.4B in Q2, and -$5.4B if you strip out prepayments. Against $8.0B of cash plus $1.6B of securities, that's anywhere from under two quarters to six-plus, before even asking what happened in Q3. Capex doubling pushes the forward number toward the high end, but "1.7 quarters" should be written as a range.

Conservative, your cost comparison is right on the payoffs and silent on the probabilities. Waiting for 240 costs about 3 percent if the stock bounces. Not waiting costs a 20 percent gap only if the stock drops before it bounces. Break-even is roughly a 15 percent chance of that sequence, and with 7 percent daily ranges over a few weeks, a touch of 240 looks much likelier than a 20 percent gap first. That's my judgment, not data. It's why I'd wait on part of the sale and still sell a third now as cheap insurance.

The bigger problem is that "we're blind, so size smaller" has no stopping point. Missing news, missing earnings date and missing macro data could justify 10 percent or zero just as easily as 20. What actually sets the number is a loss budget on a 35 percent gap. Your own 1.4 percent of portfolio example shows this: whether that's 25 or 35 percent of a standard allocation depends on how big the standard allocation is. So the percentage range matters less than the budget. Also, the $4.6B cash estimate assumes no raise and a repeat of Q2 burn, and the true figure could be anywhere from there to well above $8B. Use liquidity for direction, not for timing. An options hedge on a stock moving 7 percent a day will probably be expensive, which is the argument for owning fewer shares.

The common mistake in both plans is treating chart conditions as if they set the size. They govern the pace of selling, not the amount carried into the print. A close above 243.88 with ADX through 25 would be the first real trend confirmation in a month, so I'd stop pushing sales into it and not add. But the pre-print position stays capped at the loss-budget number whatever the chart does, because a gap at the open is the one thing the chart can't see.

The plan:

Sell about a third of the intended reduction now or this week.
Ladder limit orders at 236, 240 and 244.
If an earnings date is announced, finish the reduction before the print. Don't wait on the date alone, because it may come late.
Size the residual from the loss budget, which should land around 20 to 25 percent of a standard allocation. Put a closing stop at 199.54 on it, knowing it can gap.
Don't open a position if you have none. Better entries are a pullback into 205 to 218 once financing is clear, or a confirmed breakout.
Rebuy only on conditions: financing terms known, capex funded for several quarters, trend confirmed.

One practical thing before any of this: check the earnings date and whether anything was raised in Q3. It's the cheapest information we're missing, and it could change the schedule.

This is a risk-management trim, not a bet that the stock falls. If the print is strong and funded, you keep a core and sold some at 236 to 244. If a big raise comes, you're mostly out beforehand.

FINAL TRANSACTION PROPOSAL: SELL (a staged trim to about 20 to 25 percent of a standard allocation, not a full exit) Neutral Analyst: We've converged enough that most of what's left is argument over numbers that don't decide the outcome, so I'll say which ones those are and then pin down the few that do.

Aggressive, you've settled at 25 percent and the conservative is at 20, and each of you leans on the tail you like. You cite 148 to 278 in twelve trading days, and the conservative cites 286 to 148 in six weeks. Both are real and they cancel. On a 30 percent gap up, 25 percent of a standard allocation makes about 7.5 points of allocation and 20 percent makes 6. On a 35 percent gap down, you lose about 8.75 versus 7. The choice between them moves the result by under two points in either direction. The decision that matters is that nobody carries a full position into the print, and you've all agreed on that.

The number should come from a loss budget, and the percentage follows from the size of the standard allocation. Say you'd accept losing half a percent of the portfolio on a 35 percent gap. That caps the residual at about 1.4 percent of the portfolio. If the standard allocation is 5 percent of the portfolio, that's about 29 percent of standard. If it's 8 percent, it's about 18 percent. So 20 versus 25 is the wrong argument, and the formula settles it.

You also have a real contradiction. You promise to stop selling on a close above 243.88 with ADX through 25, but you've also promised to finish before the print once a date is announced. The conservative caught that, and I said something similar earlier. A breakout can pause the ladder and keep us from adding. It can't change the pre-print number, because a gap at the open is the one thing the chart can't see.

Conservative, I agree with you on the half-cut below 205. I proposed that tripwire earlier, and the aggressive's objection that it's nearly the same decision as 199.54 is an argument for doing it, not against. But I'd also be honest that a close below 205 is low-information. The September floor was 199.54 on 9/1 and 207.37 on 9/15, so 205 is inside the range.

Your 20 percent ceiling pre-judges what the loss budget should decide. Stack it up: a 20 percent cap, half cut at 205, and the rest gone at 199.54. Your rebuy rule also needs a close above 243.88, so you may buy back above where you sold. That's the price of insurance, and the plan should say so rather than pretend it's free.

On raises coming into strength, we have one equity raise on a rally. The earlier debt raise came when the stock was far lower, around 99 at the end of March on the insider prices. That's a thin basis for the claim. I'd still accept your backstop, since it costs little. Pick a calendar date for finishing the reduction whether or not an earnings date is announced. Two to three weeks out is my judgment, not data.

You're also right that the trailing-average runway is the least relevant number. I included six-plus quarters to show how wide the range is, but with capex doubling and deferred revenue growth slowing, the forward weight belongs on the short end. Still, you can't call Q3 cash both an unreliable runway input and a certain raise. That's why the first action is to check the earnings date and whether anything was raised in Q3. If a raise already closed, the risk of a financing before the print drops, and I'd lean toward the upper end of the residual. If nothing was raised, the funding risk is live, and I'd lean toward the lower end.

One thing neither of you raised is where the proceeds go. If the worry is the AI capex cycle, rotating into other high-beta AI or semiconductor names cuts single-name event risk but leaves the same underlying exposure. Chips rallied on 10/1 and the AI-demand headlines were constructive, but the Fed commentary was hawkish and Gundlach is warning about fragility. Those cut across the whole group, not just NBIS.

For the trader's note, I'd change these things: - Keep the Sell, but replace the single 240 entry with a ladder at 236, 240 and 244. - Sell about a third of the reduction now or this week. - Finish before the print once a date is announced, or by the backstop date. - Size the residual from the loss budget, which likely lands around 20 to 25 percent of standard. - Put a closing stop at 199.54 with a half-cut below 205, and accept that gaps can bypass both. - Open no starter position. A better entry is a pullback into 205 to 218 once financing is clearer, or a confirmed breakout. - Move the 20x multiple to a footnote, since it's our own arithmetic. - Write runway as a range. - State interest coverage honestly: about 1.3x on normalized EBITDA and negative on operating income. - Rebuy on conditions, not price.

This is a risk-management trim, not a bet that the stock falls. If the print is strong and funded, you keep a core and sold some at 236 to 244. If a big raise comes, you're mostly out beforehand.

FINAL TRANSACTION PROPOSAL: SELL (a staged trim to a loss-budget-sized residual, roughly 20 to 25 percent of a standard allocation, not a full exit) Neutral Analyst: Let me start with where each of you moved, because it matters for what's left.

Aggressive, you gave up the rebuy-lower story, accepted the ladder, took the first-third sale, and dropped the contradiction about stopping the ladder on a breakout. That's real movement. But you ended with two rules that conflict. You said the loss budget picks the number, and then you said you won't go toward 10%. A formula with a floor isn't a formula. If someone's standard allocation is 10% of the portfolio and their budget is half a percent on a 35% gap, the answer is about 14% of standard, and your floor doesn't override that. Conservative is right to call it. The plan should say the cap is 25, there is no floor, and the budget decides.

Your upside argument also keeps leaning on 148 to 278 in twelve trading days. The only single-session gap in our data is the August one, and it went up. The 286 to 148 drop took six weeks. I'm not saying a bad gap down can't happen, but the financing-day reactions I'd expect are more like 5 to 15 percent than 35. So 35% is a stress number for sizing, not a forecast, and I'd say so. That cuts both ways. It means the 20 versus 25 argument is smaller than either of you has made it, and it also means Conservative's drive toward the low end rests on a tail we haven't observed.

Conservative, you're right that 454% year over year is a base effect off a $105M quarter. Sequential growth slowing from 75 to 46 percent is the better number, and a guessed $800M Q3 would be about 37. But I don't accept that you can't use the prepayment fade to justify selling and also hold a core. Those aren't contradictory. The case for trimming is that funding gets pricier and the stock is priced for a smooth path. The case for keeping a core is that the business is real, with $6B of deferred revenue, and the stock can gap up on news we can't see. Holding some of a name you're underweight on is what an underweight is.

I'll also push on the unconditional mid-October backstop. I accept a calendar date, because without one the whole plan depends on an announcement that may come late. But I wouldn't make it so early that it forces a market sale weeks before a print that probably isn't until November. We can't confirm that date, which is why the first thing to do is check it. A backstop around mid to late October, tightened to a few days before the print if a date is announced, gets you the same protection. Arguing over one week is the decimal-point fight you already named. Make it a date, write it down, and don't renegotiate it.

On your proceeds point, Conservative, I agree with the portfolio-wide loss budget. If the cash goes into other high-beta AI or chip names, the NBIS trim removes single-name risk but keeps the capex-cycle and rates risk, and the budget is spent twice. Park it in cash or bills until the financing picture clears, unless you've decided on purpose to keep the sector exposure.

One more thing no one has raised is tax. We don't know the holder's lots or holding periods. Selling a third now, a third on a ladder and the rest by a deadline may mean different tax outcomes depending on which lots go first and whether any are short term. That shouldn't change the direction, but it can change which shares you sell, so check it before the first order.

Here is where I land. Check the earnings date and any Q3 financing today, but don't hold the first third for the answer. Sell about a third of the reduction this week. Ladder the rest at 236, 240 and 244. A close above 243.88 with ADX through 25 pauses the ladder but doesn't change the pre-print number. A close below 218.41 finishes the ladder at market. Set a calendar backstop in mid to late October, earlier if a print date is announced. Size the residual from a portfolio-wide loss budget, capped at about 25 percent of a standard allocation, with no floor. Halve it on a close below 205 and exit on a close below 199.54, knowing a closing stop can gap. Open no new position, and look for a pullback into 205 to 218 once financing is clear, or a confirmed breakout. Rebuy only on conditions: financing terms known, capex funded for several quarters, and trend confirmed. Say plainly that this may mean buying back above where you sold, because that's the cost of the insurance.

For the trader's note, drop the single 240 entry in favor of the ladder, remove the 10 to 15 percent starter, put the 20x multiple in a footnote as our own arithmetic, and show runway as a range. Interest coverage is about 1.3x on normalized EBITDA and negative on operating income.

This is a risk-management trim, not a call that the stock falls. If the print is strong and funded, you keep a core and sold some at 236 to 244. If a big raise lands, you're mostly out beforehand. Either way, nobody carries a full position into an event we can't time.

FINAL TRANSACTION PROPOSAL: SELL (a staged trim to a loss-budget-sized residual, capped at about 25% of a standard allocation with no floor, not a full exit) Neutral Analyst: We've converged enough that I'll spend this round on what's still wrong or loose in each of your positions, then give the version I'd put in the note.

Aggressive, your last turn is almost a copy of the one before it, so I'll take the new bits. The 5.5x year-over-year comparison is right arithmetic, but Conservative's point stands: any plausible Q3 prints north of 400 percent against a $146M base, so the number can't separate a great quarter from a mediocre one. Citing the August gap as proof of contracted demand also goes too far. We don't know what caused it, and you conceded that earlier. A gap on unknown news is evidence the stock can move, not evidence about the business.

You're right that 5 to 15 percent is a more plausible financing-day move than 35, but it's a judgment from this conversation, not from data. Conservative's arithmetic is also right. On a 25 percent residual, 15 percent costs nearly four points of allocation, not one or two. And 15 percent is about two ATRs, which this stock does in an ordinary bad stretch. Your 25 percent cap is fine as a ceiling, and I'm glad the floor is gone.

Conservative, you're pushing the same way on the other side. "Growth is gated by capex, and capex is gated by financing" treats financing as a barrier when the data shows it as a price. In consecutive quarters the company raised $4.3B of debt and then $2.85B of equity, so the market has been supplying capital. The risk is the cost and dilution of the next raise, which is exactly why we're trimming. It's not a reason to hold a smaller core than the loss budget allows. The same applies to your point that 15 percent is "an ordinary bad stretch." That's symmetric. Ordinary good stretches happen too, and that is why we keep a core at all.

I'd also point out that you want a hard sale on the 20^th "whatever the chart says," while wanting the unknown print date to matter. Those fit together only if the backstop is understood as reaching the pre-print size, not liquidating. If it's one number and the loss budget set it, then selling into whatever price shows up on the 20^th is consistent. If the earnings date turns out to be late November, I'd still hold the 20^th, but I'd say openly that we're paying for the financing-timing risk, not the print risk.

Two practical flaws neither of you noticed. First, a close-based stop at 199.54, and the half-cut at 205, aren't orders. They're rules that someone has to execute the next morning, at an open that can be well below. Set alerts, decide in advance that the response is automatic, and don't pretend it's a resting stop. A real intraday stop at that level would get hit by ordinary noise, since the low-day range alone is bigger than the cushion. Second, the 244 rung and the "pause the ladder on a breakout" rule conflict. A limit at 244 only fills in a breakout. I'd leave the resting limits in place and define "pause" as no market sales and no early backstop sales, which keeps the rule consistent with fixing the pre-print number.

Here's the version for the note. Today, check the earnings date and any Q3 financing, and check tax lots, but don't hold the first third for the answers. Sell about a third of the reduction this week. Rest limits at 236, 240 and 244. A close below 218.41 finishes the ladder at market. Set an unconditional backstop on or before October 20, earlier if a date is announced, and write it down now. Size the residual from a portfolio-wide loss budget, capped at 25 percent of a standard allocation, with no floor, and likely lower if your standard allocation is large. Halve it on a close below 205 and exit on a close below 199.54, accepting that gaps can bypass both. Park proceeds in cash or bills, not in correlated AI names. Open nothing new, and look for a pullback into 205 to 218 once financing is clear or a confirmed breakout. Rebuy on conditions, and say plainly that it may cost more than you sold for. Put the 20x multiple in a footnote as our own arithmetic, show runway as a range, and state interest coverage as about 1.3x on normalized EBITDA and negative on operating income.

This is risk management, not a call that the stock falls. The debate is now about decimal points, and the decisions that matter, no full position into the print and conditions-based re-entry, are settled.

FINAL TRANSACTION PROPOSAL: SELL (a staged trim to a loss-budget-sized residual, capped at about 25% of a standard allocation with no floor, with an unconditional backstop on or before October 20, not a full exit)

V. Portfolio Manager Decision¶

Portfolio Manager¶

Rating: Underweight

Executive Summary: Cut NBIS before the Q3 print and the expected financing, but don't exit. Sell about a third of the planned reduction this week. Rest limit orders at 236/240/244 for the rest, and sell anything still unsold at market by October 20 at the latest (earlier if an earnings date is announced). Size what's left from a portfolio-wide loss budget: capped at 25% of a standard allocation, no floor. Halve it on a daily close below 205 and exit on a close below 199.54. Open no new position, keep the proceeds in cash or bills, and only rebuy on stated conditions. Re-evaluate right after the Q3 print or any financing, whichever comes first.

Investment Thesis: Decision: Underweight, not Sell or Hold. All three risk analysts wrote "SELL", but each one described a staged trim to a residual position, explicitly "not a full exit". That matches Underweight (reduce exposure) better than Sell (exit or avoid). The research manager also landed on Underweight, so I'm treating the trader's Sell as a label problem, not a different plan.

Why reduce: the bear case wins on the next 1–3 months. 1) Funding gap. In Q2, operating cash flow was $2.25B, but about $2.03B of that came from working capital: customer prepayments of about $1.2B plus a one-off receivables collection of about $1.14B. That leaves underlying operating cash of about $0.2B against $5.66B of capex, and free cash flow of -$3.41B. The prepayment tailwind is fading: deferred revenue rose about $3.2B in Q1 but only about $1.2B in Q2. Runway is a range. The $8.04B cash balance plus $1.6B of securities lasts under 2 quarters at the stripped burn rate and about 3 at the reported one. The cash figure is also as of June 30, so it is three months stale. Another raise is likely, and gaps on that news bypass stops. 2) Cost of capital. Interest rose from $4.8M to $119.1M a quarter, about $475M annualized. That compares with about $617M of annualized normalized EBITDA, so coverage is about 1.3x, and it is negative on operating income. Diluted shares rose about 11% in six months. 3) Asymmetry. Valuation is the debaters' own arithmetic, since there is no vendor data: 272M shares × $232 ≈ $63B, against a run-rate of about $3.2B if Q3 comes in near $800M. That is roughly 20x forward and high-20s trailing. A clean $808M quarter barely moves that multiple. Sequential growth already slowed from 75% to 46%, and operating margin stalled at about -30%. Depreciation on $14.9B of PP&E (up from $8.4B) is still to come. 4) Technicals don't help. The stock is range-bound, with ADX at 18.6. Closing highs are stepping down (286.69 → 277.68 → 243.88 → 243.48), and price is sitting on its 10 EMA with ATR at about 6.9% of price. Insiders have made no open-market buys. That's a small negative and not a trigger.

Why not Sell: the business is real. Revenue is $582M, up 454% year over year. Deferred revenue is about $6.0B, and normalized EBITDA is positive. The long-term structure is intact: price is above the 50 and 200 SMAs, and weekly and monthly SuperTrend are both up. OBV made a higher high on the second test of 243, and the stock has gapped up 34% in a single day before. The balance sheet isn't distressed; the risk is the price of the next financing, not solvency. A core position keeps the upside tail.

Where the debate settled things: no full position into an event we can't time. Selling a third now is cheap insurance against a gap before any bounce, which answers the conservative's point. Resting the ladder near resistance avoids dumping mid-range, which answers the aggressive and neutral points. The backstop is unconditional, and a breakout can pause market sales but can't change the size held into the print. Residual sizing follows the neutral analyst's formula: loss budget ÷ 0.35 stress gap, counted across correlated AI/semiconductor holdings. That gives a cap of 25% of standard with no floor. This tightens the research manager's 25–35% range. I'm also dropping the 10–15% token starter for new buyers; both the conservative and neutral analysts showed it only adds exposure to an event we can't time.

Price target, $218 over 1–3 months: two independent anchors agree. (a) Dilution math. Recurring dilution of about 23% annualized works out to about 5.75% per quarter. One quarterly-sized raise at a constant market-cap-to-sales multiple gives 232.28 / 1.0575 ≈ $219.6. (b) Technicals. The 50 SMA is at 218.41, in the lower half of the expected 205–245 chop, with the Bollinger middle at 227.9 and the lower band at 205.1. That puts the base case at about $218, roughly 6% below today's price. The upside scenario is a ~$1B quarter, which re-rates the stock toward 250.68 and 277.68. The downside scenario is a stall plus a discounted raise, which tests 199.54 and 195.10.

What would change the call: - Back to about 50% of standard after a Q3 print with revenue at or above $800M, operating margin better than -30%, and a net deferred-revenue increase of about $1.2B or more. - Overweight once financing is done on non-punitive terms, capex is funded for several quarters, and the stock closes above 243.88 on volume with ADX above 25. That may mean buying back above where we sold; that's the cost of the insurance. - Toward Sell on any of: a decline in deferred revenue, delivery slippage, a large discounted equity raise, expensive new debt pushing interest well above $119M a quarter, or operating margin worse than -30%.

Open items: no earnings date, and no confirmation of whether a raise happened in Q3 (check both today). Net debt doesn't reconcile ($503.6M reported vs. about $2.1B computed), so don't use it. No customer-concentration disclosure. No options pricing. Check tax lots before selling.

Current Price: 232.28

Price Target: 218.0

Confidence: Medium

Time Horizon: 1-3 months